Trending Topics in Gastroenterology | GastroAGI

Risk Factors for Portal Vein Thrombosis in Liver Cirrhosis

Portal vein thrombosis (PVT) is a significant complication in patients with liver cirrhosis (LC), as it exacerbates portal hypertension and accelerates progression toward decompensation. Risk factors for PVT in cirrhotic patients can be categorized into four primary domains: **hemodynamic disturbance**, **cirrhosis severity**, **endothelial injury with hypercoagulability**, and **thrombophilic genetics**. Below is a detailed breakdown of these risk factors: --- ### **1. Hemodynamic Disturbance** - **Decreased Portal Vein Velocity (PVV):** - A PVV of less than 15 cm/s promotes blood stasis, which is a critical factor for thrombosis formation. - **Portal Vein Dilation:** - Dilation of the portal vein (> 14.5 mm) reduces flow velocity and leads to vortex formation, increasing the risk of thrombosis. - **Splenic Vein Dynamics:** - Splenic vein dilation and reduced velocity are strong predictors of PVT, especially post-splenectomy, as thrombosis often originates in the splenic vein. --- ### **2. Cirrhosis Severity** - **Portal Hypertension:** - Higher portal pressure (HVPG ≥ 16–20 mmHg) is strongly associated with PVT development. - **Complications of Cirrhosis:** - Ascites, variceal bleeding, and hepatic encephalopathy are markers of advanced cirrhosis and increase PVT risk. - **Liver Function Markers:** - Low serum albumin levels, Child–Turcotte–Pugh (CTP) scores of B or C, and higher MELD scores independently predict PVT occurrence. --- ### **3. Endothelial Injury with Hypercoagulability** #### **Iatrogenic Causes:** - **Splenectomy:** - This surgical procedure increases PVT risk by ≥ 10-fold due to mechanical disruption of blood flow and endothelial injury. - **Endoscopic Variceal Treatments:** - Procedures for variceal bleeding can cause mechanical injury to the endothelium, elevating PVT risk. #### **Inflammation and Endotoxemia:** - **Bacterial Translocation:** - Migration of bacteria from the gut into systemic circulation triggers cytokine activation, damaging the endothelium. - **Inflammatory Markers:** - Elevated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are predictive markers for inflammation-related PVT. #### **Emerging Biomarkers:** - **Phosphatidylserine-positive Microparticles (PS+MPs):** - These microparticles create a pro-thrombotic environment. - **Neutrophil Extracellular Traps (NETs):** - NETs contribute to a hypercoagulable state and endothelial injury. #### **Metabolic Factors:** - **Diabetes Mellitus:** - Diabetes promotes endothelial dysfunction and hypercoagulability. - **Hypertension and Obesity:** - Both conditions are additional risk factors for PVT. #### **Coagulation Imbalance:** - **Elevated D-Dimer:** - Levels > 0.87 µg/mL reflect increased clot formation and fibrinolysis. - **Mean Platelet Volume (MPV):** - Higher MPV indicates platelet activation and hypercoagulability. - **P-Selectin (CD62P):** - Elevated levels are markers of platelet activation and thrombus formation. #### **CAF Imbalance:** - **Factor VIII/Protein C Ratio:** - Disruption in this ratio indicates a loss of coagulation–anticoagulation balance. - **vWF/ADAMTS-13 Ratio:** - An imbalance here also reflects hypercoagulability. --- ### **4. Thrombophilic Genetic Mutations** - **Factor V Leiden Mutation:** - This mutation increases susceptibility to PVT, particularly in Caucasian populations. - **Prothrombin G20210A Mutation:** - Another genetic variant strongly associated with PVT risk in Caucasians. - **MTHFR C677T Mutation:** - This mutation is linked to hyperhomocysteinemia and thrombosis risk. - **JAK2 V617F Mutation:** - Associated with myeloproliferative disorders and increased thrombosis risk. - **Ethnic Differences:** - FV Leiden and G20210A mutations are more prevalent in Caucasians, while Protein C (PROC) variants are significant in Asian populations. --- ### **Risk Stratification** - **High-Risk Factors:** - Examples include splenectomy, low portal vein velocity (< 15 cm/s), and elevated D-dimer (> 0.87 µg/mL). - **Medium-Risk Factors:** - Conditions such as diabetes mellitus, Child–Turcotte–Pugh B/C classification, and moderate elevations in inflammatory markers. - **Clinical Guidance:** - High-risk patients require regular Doppler ultrasound screening and selective anticoagulation therapy. --- ### **Pathophysiology Insight** PVT development in cirrhotic patients is the result of complex interactions between hemodynamic disturbances, inflammatory processes, endothelial injury, and genetic predispositions. It is rarely caused by isolated factors but rather by the interplay of multiple risk domains. --- ### **Future Directions** - Validation of new biomarkers such as PS+MPs and NETs. - Establishment of definitive cutoff values for predictive markers. - Creation of integrated models to predict PVT risk more accurately. --- ### **Conclusion** Early identification of risk factors and proactive management strategies, including regular screening and targeted prevention, can significantly reduce complications and improve outcomes for cirrhotic patients at risk of portal vein thrombosis.

Prediction of the Risk of Developing Severe Liver Disease

The CORE model, developed by researchers at Karolinska Institutet, predicts the 10-year risk of developing severe liver diseases, such as cirrhosis and liver cancer, using a simple blood test. It combines three routinely measured liver enzyme levels (AST, ALT, GGT) with age and sex. The model demonstrated 88% predictive accuracy, outperforming the widely used FIB-4 method, and is particularly suited for primary care settings. Validated in cohorts from Finland and the UK, it is accessible via a web-based calculator (www.core-model.com). Further testing among high-risk groups is needed, and efforts are underway to integrate it into electronic medical record systems for streamlined clinical use.

Antibiotics prophylaxis in GI bleeding in Cirrhosis Liver

### Antibiotic Prophylaxis in Gastrointestinal (GI) Bleeding in Cirrhosis: A Comprehensive Overview Antibiotic prophylaxis has been a cornerstone in the management of cirrhotic patients with upper gastrointestinal (GI) bleeding for decades. However, recent advancements in bleeding management and a better understanding of infection risks have prompted a reevaluation of this practice. Below is a detailed analysis of the topic based on contemporary evidence and expert opinion. --- ### **1. Historical Context** - **Rationale for Prophylaxis:** Antibiotic prophylaxis became standard in the management of variceal GI bleeding in cirrhotic patients because of the high prevalence of bacterial infections (up to 60%) in earlier decades. These infections were associated with increased risks of rebleeding and mortality. - **Impact of Infections:** Infections in cirrhotic patients significantly worsen outcomes by increasing portal hypertension, impairing clotting mechanisms, and triggering systemic inflammation. --- ### **2. Current Challenges** - **Improved Bleeding Management:** Advances in endoscopic techniques, vasoactive drugs, and supportive care have reduced the overall risk of complications like infections and rebleeding. This raises the question of whether prophylactic antibiotics still provide a significant mortality benefit in the modern era. - **Potential Overuse:** Routine use of antibiotics for up to 7 days, as recommended by international guidelines, may represent overtreatment for some patients, especially those at lower risk of infection. --- ### **3. Evidence from Systematic Review and Meta-Analysis** A systematic review and meta-analysis of 14 randomized controlled trials (RCTs) involving 1,322 patients assessed the efficacy and necessity of antibiotic prophylaxis in cirrhotic patients with upper GI bleeding. #### **Key Findings:** 1. **Mortality Outcomes:** - Shorter antibiotic courses (2–3 days) or no prophylaxis were **noninferior** to longer courses (5–7 days) in terms of all-cause mortality. - Probability of noninferiority: 97.3%. - Risk difference: 0.9% (95% Credible Interval [CrI], –2.6% to 4.9%). 2. **Rebleeding Risk:** - Shorter courses had a 73.8% probability of noninferiority for early rebleeding. - However, the credible interval (–4.2% to 10%) suggests some uncertainty. 3. **Infection Risk:** - Shorter or no prophylaxis was associated with a higher rate of bacterial infections (risk difference 15.2%). - Infection definitions varied significantly across trials, making it difficult to draw definitive conclusions. 4. **Era of Trials:** - Studies conducted after 2004 showed stronger probabilities of noninferiority for both mortality and rebleeding, likely reflecting improvements in overall bleeding management. 5. **Adverse Events:** - None of the trials adequately reported adverse drug events, leaving gaps in understanding the safety profile of prophylactic antibiotics. --- ### **4. Implications for Guidelines** - **Current Recommendations:** International guidelines recommend up to 7 days of prophylactic antibiotics in cirrhotic patients with upper GI bleeding to prevent infections and improve outcomes. - **Reassessment Needed:** Evidence suggests that prolonged prophylaxis may not be necessary for all patients. Routine use could represent overtreatment, particularly in low-risk groups such as Child-Pugh A patients. - **Selective Use:** Experts advocate for a more tailored approach, identifying subgroups (e.g., Child-Pugh B/C patients) who may benefit most from antibiotics. --- ### **5. Risks of Antibiotic Prophylaxis** While generally considered safe, antibiotic prophylaxis is not without risks: - **Adverse Effects:** Gastrointestinal disturbances, allergic reactions, and other side effects. - **Clostridioides difficile Infection:** Increased risk of C. difficile colitis, particularly with broad-spectrum antibiotics. - **Antibiotic Resistance:** Prolonged use contributes to the development of multidrug-resistant organisms, a growing global health concern. --- ### **6. Analogies with Other Infections** In other infectious conditions, shorter antibiotic courses have been shown to be equally effective or even superior to longer courses. This trend supports the idea of questioning prolonged prophylactic antibiotic use in cirrhotic patients with GI bleeding. --- ### **7. Practice Inertia** Despite emerging evidence, the practice of routine prophylaxis persists due to: - Historical precedent set during an era of higher infection risks. - Lack of robust, high-quality data to definitively abandon the practice. --- ### **8. Future Research Directions** To address current gaps, future trials should: - Focus on defined cirrhotic populations (e.g., Child-Pugh A vs. B/C). - Compare shorter vs. no antibiotic prophylaxis. - Use standardized definitions for infection outcomes. - Report adverse events and antibiotic resistance rates. - Include clear endpoints like mortality, rebleeding, and infection rates. --- ### **9. Clinical Implications** - **Prolonged Prophylaxis:** May not be necessary for all cirrhotic patients with upper GI bleeding, particularly those at lower risk of infection. - **Selective and Shorter Use:** A reasonable interim strategy while awaiting more robust evidence. - **Guideline Evolution:** Recommendations are likely to evolve cautiously, balancing the risks of infection with those of antibiotic overuse. --- ### **10. Expert Commentary** Experts like Mezzacappa and Garcia-Tsao from Yale emphasize that while it may be time to revisit the widespread use of prophylactic antibiotics, the current evidence is insufficient to completely abandon the practice. A precision medicine approach—targeting antibiotics to those most likely to benefit—may be the optimal strategy moving forward. --- ### **Summary** Antibiotic prophylaxis remains a critical component of managing cirrhotic patients with upper GI bleeding, but its routine use for up to 7 days is increasingly being questioned. Emerging evidence suggests that shorter or selective prophylaxis may be equally effective in many cases, particularly in the context of modern bleeding management. Until high-quality trials provide definitive answers, clinicians should weigh the risks and benefits on a case-by-case basis, focusing on individual patient risk profiles.

Ultra-early (16 years) predictive model for MASLD

The ultra-early predictive model for **Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)** is a promising development in preventive healthcare. This model relies on identifying specific protein changes in the blood, such as **GGT1**, which can signal a higher risk of developing MASLD up to **16 years before symptoms appear**. Here's a detailed explanation of the model: ### Key Features of the Predictive Model: 1. **Protein Biomarkers**: - Certain proteins, like **GGT1**, are associated with early metabolic changes that eventually lead to MASLD. - These protein changes can be detected in blood tests long before any physical symptoms or liver damage are evident. 2. **Integration with Health Measures**: - The predictive model becomes even more accurate when combined with simple health metrics such as: - **Body weight** - **Exercise levels** - **Other lifestyle factors** - This integration allows for a more comprehensive risk assessment. 3. **Ultra-Early Detection**: - The ability to detect MASLD risk up to **16 years in advance** is a groundbreaking feature. - This gives a long window of opportunity to implement preventive measures. 4. **Preventive Steps**: - Early identification of high-risk individuals allows doctors to recommend lifestyle changes, such as: - **Adopting a healthy diet** - **Increasing physical activity** - **Regular monitoring of liver health** - These steps can potentially prevent the onset of MASLD or slow its progression. 5. **Reducing the Burden of MASLD**: - MASLD is closely linked to conditions like **obesity**, **diabetes**, and **heart disease**. - By addressing risk factors early, this model could help reduce the growing prevalence of MASLD and its associated complications. 6. **Comparison to Heart Disease Risk Calculators**: - Similar to tools used for predicting heart disease risk, this model could become a standard tool for planning liver health. - It empowers both patients and doctors to make informed decisions about long-term health management. ### Potential Impact: - **Personalized Prevention**: - The model supports tailored interventions based on an individual's specific risk profile. - **Healthcare System Benefits**: - Early intervention could reduce the economic and healthcare burden associated with advanced liver disease. - **Public Health**: - Promoting awareness of MASLD risk factors could lead to healthier lifestyle choices on a broader scale. ### Next Steps: - **Further Research**: - While the study shows strong potential, more research is needed to validate and refine the model. - Large-scale studies and clinical trials will be essential to confirm its effectiveness. - **Implementation**: - Once validated, the model could be integrated into routine health check-ups, especially for individuals at higher risk due to obesity, diabetes, or other metabolic conditions. ### Conclusion: The ultra-early predictive model for MASLD represents a significant advancement in preventive medicine. By identifying high-risk individuals up to 16 years before symptoms appear, it offers a unique opportunity to intervene early with lifestyle changes and monitoring. This approach could help mitigate the rising burden of MASLD and improve long-term liver health outcomes.

Hepatic recompensation in patients with decompensated cirrhosis – What is new?

Hepatic recompensation in patients with decompensated cirrhosis has emerged as a transformative concept in liver disease management, challenging the long-held belief that cirrhosis is irreversible. Recent advancements have expanded our understanding of recompensation, defined by the Baveno VII consensus as control or cure of the underlying cause, resolution of ascites and encephalopathy without medication, no variceal bleeding for 12 months, and restoration of liver function to Child-Turcotte-Pugh (CTP) class A. Here's what's new in this field: --- ### **1. Paradigm Shift: Reversibility of Cirrhosis** Cirrhosis, once deemed a permanent condition, is now understood to be reversible in certain cases if the underlying causal factors are effectively managed. This shift has been driven by interventions targeting viral hepatitis, alcohol use disorder, autoimmune diseases, and metabolic dysfunction-associated liver disease (MASLD, formerly NAFLD). --- ### **2. Advances in Management of Underlying Causes** Recompensation is most achievable in cirrhosis caused by hepatitis C virus (HCV), hepatitis B virus (HBV), and alcohol-related liver disease. Emerging evidence also suggests the possibility of recompensation in MASLD, autoimmune liver diseases, primary biliary cholangitis (PBC), and Wilson’s disease. #### **HCV:** - Direct-acting antivirals (DAAs) have revolutionized HCV treatment, achieving sustained virological response (SVR) in 80–90% of decompensated patients. - Approximately 25% of patients meet Baveno VII recompensation criteria post-treatment, with improved MELD/CTP scores and reduced complications. - However, the risk of hepatocellular carcinoma (HCC) persists, necessitating ongoing surveillance. #### **HBV:** - Long-term nucleos(t)ide analogue therapy (e.g., entecavir, tenofovir) improves survival and reduces decompensation events in HBV-related cirrhosis. - Over 50% of patients in some cohorts achieve recompensation, demonstrating the effectiveness of antiviral therapy. #### **Alcohol-Associated Cirrhosis:** - Studies show that 8–18% of decompensated patients achieve recompensation with sustained abstinence. - Predictors of recompensation include lower baseline MELD scores, lower hepatic venous pressure gradient (HVPG), higher albumin levels, and female sex. - Relapse prevention remains critical to maintaining recompensation. #### **MASLD and Obesity:** - Although no standard drug therapy exists, weight loss (via lifestyle modifications or bariatric surgery in selected patients) has shown promise in improving liver function. - Early reports suggest that recompensation may be possible in MASLD-related cirrhosis, though further research is needed. #### **Autoimmune Liver Diseases and PBC:** - Small studies indicate that immunosuppressive therapy in autoimmune hepatitis and ursodeoxycholic acid (UDCA) in PBC can lead to recompensation. - However, progression and relapse remain common, and lifelong HCC surveillance is recommended. --- ### **3. Biological Mechanisms of Recompensation** Recompensation is driven by several biological processes, including: - **Collagen degradation and fibrosis regression:** Reduction of scar tissue improves liver architecture and function. - **Vascular remodeling:** Decreased portal hypertension reduces complications like ascites and variceal bleeding. - **Reduced hepatic inflammation:** Suppression of inflammatory pathways contributes to improved liver function. --- ### **4. Role of TIPS (Transjugular Intrahepatic Portosystemic Shunt)** TIPS placement can control portal hypertension, ascites, and variceal bleeding. Approximately 24% of decompensated patients achieve recompensation post-TIPS, though it remains unclear whether the benefit is primarily due to TIPS itself or effective management of the underlying disease. --- ### **5. Predictive Models for Recompensation** Emerging predictive tools combine clinical and biochemical factors to estimate the likelihood of recompensation: - **BE3A (for HCV):** Incorporates bilirubin, albumin, and INR. - **BC2AID and Brec-PAS (for HBV):** Include bilirubin, albumin, INR, BMI, and complications. These models are promising but not yet widely adopted in clinical practice. --- ### **6. Persistent Portal Hypertension** Even after recompensation, portal hypertension may persist, requiring continued management: - HVPG reductions are not always accompanied by variceal regression, necessitating surveillance and beta-blocker use. - Non-selective beta-blockers should not be discontinued unless HVPG falls below 10 mmHg due to ongoing risk of rebleeding and decompensation. --- ### **7. Hepatocellular Carcinoma (HCC) Risk** Recompensation lowers but does not eliminate HCC risk: - Annual HCC incidence rates remain at 1–3% in recompensated HBV and HCV cirrhosis patients. - Lifelong surveillance is essential, even for patients with functional recovery. --- ### **8. Transplant Delisting** Recompensation can lead to delisting from liver transplant waitlists: - Reports show that 6–10% of patients, particularly those with HBV, HCV, or alcohol-related cirrhosis, can be safely delisted due to clinical improvement. - This has significant implications for organ allocation and resource utilization. --- ### **9. Outcomes Compared to Compensated Cirrhosis** Recompensated patients achieve survival rates closer to those with compensated cirrhosis. However, they remain at higher risk of HCC and certain complications, necessitating ongoing monitoring and care. --- ### **10. Limitations of Current Criteria** The Baveno VII criteria for recompensation exclude patients on diuretics or prophylactic lactulose, potentially underestimating real-world recompensation rates. Many clinically improved patients remain on supportive medications, highlighting the need for more inclusive definitions. --- ### **11. Research Gaps and Future Directions** - **Mechanisms and Durability:** More prospective studies are needed to define the biological mechanisms, timelines, and long-term durability of recompensation. - **Biomarkers:** Current markers like MELD and CTP scores have limitations. Non-invasive biomarkers and machine learning models may improve patient selection and outcome prediction. - **Emerging Therapies:** Novel treatments targeting fibrosis regression, portal hypertension, and the gut-liver axis are under investigation. --- ### **12. Public Health Implications** Efforts to reduce alcohol consumption, eliminate viral hepatitis, and manage obesity could significantly increase recompensation rates, reduce liver transplant needs, and improve outcomes, especially in resource-limited settings. --- ### **Conclusion** The concept of hepatic recompensation represents a major advancement in the management of decompensated cirrhosis. While significant progress has been made in understanding its mechanisms and predictors, challenges remain in optimizing patient selection, improving long-term outcomes, and addressing persistent risks like portal hypertension and HCC. Ongoing research and public health initiatives hold promise for expanding the reach and impact of recompensation in cirrhosis care.

Acute variceal bleeding in patients with cirrhosis and portal hypertension- APASL 2025

The management of **acute variceal bleeding (AVB)** in patients with cirrhosis and portal hypertension has been updated in the **Asia-Pacific Association for the Study of the Liver (APASL) 2025 guidelines**. These guidelines emphasize early diagnosis, rapid intervention, and standardized care to improve outcomes and reduce mortality. Below is a detailed summary of the key aspects of AVB management as per the APASL 2025 recommendations: --- ### **Clinical Importance** - **Acute variceal bleeding (AVB)** is a life-threatening complication of portal hypertension, with a **6-week mortality of 10–20%**. - Timely intervention and adherence to updated protocols are critical for improving survival rates. --- ### **Updated Definitions** 1. **AVB Definition**: - Defined as **hematemesis** (vomiting blood) or **melena** (black tarry stools) within **24 hours** of presentation in suspected portal hypertension. - This narrower definition helps distinguish AVB from re-bleeding episodes. 2. **Episode Duration**: - An AVB episode is defined as lasting **48 hours** from the onset of the first bleed (**T0**). - Any bleeding within this timeframe is considered part of the same episode. 3. **Re-Bleeding Categories**: - **Very early re-bleeding**: 48–120 hours. - **Early re-bleeding**: 6–42 days. - **Late re-bleeding**: Beyond 42 days. --- ### **Outcome Measures** - Expanded outcome measures include: - Survival rates. - Duration of ICU and hospital stay. - Development of new decompensations (e.g., ascites, jaundice, encephalopathy). - **MELD score** changes. - Quality of life assessments. --- ### **Time Zero (T0) and Home-to-Door Time** 1. **T0 (Time Zero)**: - Redefined as the **onset of the first bleed**, not hospital arrival. - This allows better assessment of pre-hospital delays and early interventions. 2. **Home-to-Door Time**: - Patients should reach the hospital ideally within **2 hours** (maximum **4 hours**) after the first bleed. - Delays beyond **6 hours** significantly increase mortality. --- ### **Diagnosis and Severity Assessment** 1. **Diagnosis**: - Initial evaluation includes: - **History**: Risk factors like alcohol use, hepatitis B/C, or metabolic-associated steatotic liver disease (MASLD). - **Physical exam**: Signs like ascites, jaundice, and splenomegaly. - **Laboratory tests**: Low platelets, high INR, elevated bilirubin. - **Imaging**: Ultrasound or CT for portal hypertension. - **Upper GI endoscopy** is the **gold standard** for diagnosis. 2. **Severity Assessment**: - Predictors of severe bleeding include: - High **hepatic venous pressure gradient (HVPG)**. - Alcoholic liver disease. - Infection. - High **Child-Turcotte-Pugh (CTP)** or **MELD** score. - Portal vein thrombosis. - Active bleeding on endoscopy. - The **APASL Bleed Severity Score** (0–7) is recommended for stratifying risk. --- ### **Pre-Hospital and Emergency Management** 1. **Initial Resuscitation**: - Prioritize **airway**, **breathing**, and **circulation** (ABC). - Use **conservative fluid resuscitation** to avoid overcorrection. - Target hemoglobin levels of **7–8 g/dL** with cautious transfusions. 2. **Pharmacotherapy**: - Start **vasoactive agents** (terlipressin, somatostatin, or octreotide) within **30 minutes** of the first bleed. - **Terlipressin infusion** is preferred. - Administer prophylactic **antibiotics** (e.g., ceftriaxone) for **2–5 days** to prevent infections. --- ### **Endoscopic Therapy** 1. **Timing**: - Endoscopy should be performed within **12 hours** of stabilization, preferably within **6 hours**. - Delayed endoscopy worsens outcomes. - Bedside endoscopy in the ICU is acceptable for unstable patients. 2. **Therapeutic Options**: - **Esophageal varices**: Endoscopic variceal ligation (**EVL**) is the first-line therapy. - **Gastric varices**: Cyanoacrylate glue injection is preferred. - Combination therapy (endoscopic + vasoactive drugs) is superior to either alone. 3. **Sedation and Prokinetics**: - **Propofol** or **midazolam** sedation is safe, but minimal intubation is advised. - Prokinetics (e.g., erythromycin, metoclopramide) improve mucosal visualization and reduce repeat procedures. --- ### **Rescue Therapies** - If bleeding persists despite combined medical and endoscopic treatment: 1. **Balloon tamponade** or **self-expanding metal stents** can provide temporary hemostasis. 2. **Transjugular intrahepatic portosystemic shunt (TIPS)**: - Recommended within **72 hours** (ideally <24 hours) for high-risk patients. - Improves survival in cases of uncontrolled bleeding. --- ### **Radiology and Surgery** 1. **Interventional Radiology**: - Plays a critical role in managing **complex gastric varices** or **refractory bleeding**. 2. **Surgical Options**: - Surgical shunts are rarely used but may be considered as a **last-resort option**. --- ### **Special Populations** 1. **Children**: - AVB management in children requires tailored approaches based on age and etiology. 2. **MASLD-Related Cirrhosis**: - AVB in metabolic-associated steatotic liver disease may require additional considerations. 3. **Patients on Anticoagulants**: - Risk–benefit assessment is crucial for balancing bleeding risk with thrombotic risk. 4. **Hepatocellular Carcinoma (HCC)**: - AVB in HCC patients requires individualized management. --- ### **Research and Future Directions** - **Artificial Intelligence (AI)**: Development of predictive models for AVB risk stratification. - **Novel Hemostatic Devices**: Research on innovative tools for bleeding control. - **Biomarkers**: Identification of better biomarkers for early diagnosis and prognosis. - **Early TIPS Trials**: Further studies on the timing and indications for early TIPS. - **Region-Specific Data**: Emphasis on generating data specific to Asia-Pacific populations. --- ### **Conclusion** The APASL 2025 guidelines provide a comprehensive framework for the management of acute variceal bleeding in patients with cirrhosis and portal hypertension. Early diagnosis, rapid initiation of therapy, and standardized care, along with the use of advanced interventions like TIPS and interventional radiology, are key to improving patient outcomes. Tailored approaches for special populations and ongoing research into novel therapies are also prioritized.

Systemic therapies in patients HCC who also have advanced liver dysfunction (Child-Pugh class B)

GastroAGIDashboardDocumentsUpload DocumentsUsersUser ActivityRecent ChatSections ManageCustom QuestionsEmail TemplateConferenceGastroAGICirrhosis Liver2025NovemberClinical Challenge: Most pivotal HCC trials excluded Child-Pugh B patients, so systemic therapy in this group remains controversial. This leaves a large evidence gap for real-world decision-making. Guideline Variability: Western guidelines (AASLD, EASL, NCCN, ASCO, ESMO) differ in recommendations. Most endorse systemic therapy only in Child-Pugh A, with some cautiously allowing B7–B8 if performance status is good. Heterogeneity of Child-Pugh B: This class includes both compensated patients with mild biochemical abnormalities and decompensated patients with refractory ascites or encephalopathy. Prognosis varies widely within the subgroup. Survival Outcomes: Median overall survival drops dramatically: ~16 months in Child-Pugh A, ~6 months in Child-Pugh B, and <3 months in Child-Pugh C, underscoring the impact of liver dysfunction on prognosis. Alternative Assessments: Tools like ALBI grade and MELD score provide more objective measures of liver function, though they also have limitations. ALBI can stratify survival even within Child-Pugh A and B groups. Tumor-Related Dysfunction: Large tumors, macrovascular invasion, or necrosis can worsen liver function. In some cases, systemic therapy reducing tumor burden may improve hepatic reserve and allow “recompensation.” Cirrhosis-Related Dysfunction: Active viral hepatitis, alcohol use, or MASLD drive inflammation and decompensation. Managing these etiologies alongside systemic therapy is critical for patient stability. Recompensation Potential: Retrospective studies show recompensation in 12–56% of decompensated cirrhosis patients after etiological treatment (e.g., HBV antivirals, HCV DAAs, alcohol abstinence). This influences therapy eligibility. Portal Hypertension Management: Treating varices, portal vein thrombosis, and using non-selective beta-blockers or endoscopic therapy lowers risks of decompensation and improves tolerance to cancer therapies. TKI Hepatotoxicity: Sorafenib, lenvatinib, Cabozantinib, and regorafenib can cause reversible hepatocyte injury. Adverse events like transaminase or bilirubin elevation occur in 10–25%, with <1% mortality. ICI Hepatotoxicity: Immune checkpoint inhibitors (ICIs) bypass liver metabolism but may trigger immune-mediated hepatitis. Most cases resolve with corticosteroids, and low-grade events may correlate with better outcomes. Bleeding Risks: Anti-VEGF therapies (like bevacizumab) can cause variceal bleeding, though real-world rates are low (≈3%). Risk rises in patients with prior bleeds or macrovascular invasion. Potential Portal Pressure Benefit: Preclinical and pilot studies suggest VEGF blockade may reduce portal hypertension, but this remains experimental without large clinical validation. Sorafenib Data: The largest real-world registry (GIDEON) showed median OS of 5.2 months in Child-Pugh B versus 13.6 months in A. Adverse event rates were similar, but outcomes worsened with higher B scores. Other TKIs: Data for lenvatinib, regorafenib, and Cabozantinib in Child-Pugh B are limited. All confirm worse survival than in A patients but suggest possible modest benefit in carefully selected cases. Immunotherapy Evidence: CheckMate040 included Child-Pugh B patients, showing median OS of 7.6 months with nivolumab, with some patients improving from B to A after treatment response. Meta-Analyses: Pooled data confirm shorter survival in Child-Pugh B but show comparable safety and meaningful radiological responses (ORR ~14%, DCR ~46%), supporting cautious use. Comparative Studies: Retrospective cohorts suggest ICIs may provide better survival than TKIs or best supportive care (7.5 vs. 4 months). However, regional and selection biases limit generalizability. Decision Framework: Proposed algorithms suggest systemic therapy for B7 without ascites, possible therapy for B7 with ascites or B8 if recompensation potential exists, and best supportive care for B9 or unstable decompensation. Research Needs: Large prospective trials in Child-Pugh B are unlikely due to industry hesitancy, so real-world data, investigator-led studies, and biomarker-driven stratification are urgently needed to guide practice.astroAGIDashboardDocumentsUpload DocumentsUsersUser ActivityRecent ChatSections ManageCustom QuestionsEmail TemplateConferenceGastroAGICirrhosis Liver2025NovemberClinical Challenge: Most pivotal HCC trials excluded Child-Pugh B patients, so systemic therapy in this group remains controversial. This leaves a large evidence gap for real-world decision-making. Guideline Variability: Western guidelines (AASLD, EASL, NCCN, ASCO, ESMO) differ in recommendations. Most endorse systemic therapy only in Child-Pugh A, with some cautiously allowing B7–B8 if performance status is good. Heterogeneity of Child-Pugh B: This class includes both compensated patients with mild biochemical abnormalities and decompensated patients with refractory ascites or encephalopathy. Prognosis varies widely within the subgroup. Survival Outcomes: Median overall survival drops dramatically: ~16 months in Child-Pugh A, ~6 months in Child-Pugh B, and <3 months in Child-Pugh C, underscoring the impact of liver dysfunction on prognosis. Alternative Assessments: Tools like ALBI grade and MELD score provide more objective measures of liver function, though they also have limitations. ALBI can stratify survival even within Child-Pugh A and B groups. Tumor-Related Dysfunction: Large tumors, macrovascular invasion, or necrosis can worsen liver function. In some cases, systemic therapy reducing tumor burden may improve hepatic reserve and allow “recompensation.” Cirrhosis-Related Dysfunction: Active viral hepatitis, alcohol use, or MASLD drive inflammation and decompensation. Managing these etiologies alongside systemic therapy is critical for patient stability. Recompensation Potential: Retrospective studies show recompensation in 12–56% of decompensated cirrhosis patients after etiological treatment (e.g., HBV antivirals, HCV DAAs, alcohol abstinence). This influences therapy eligibility. Portal Hypertension Management: Treating varices, portal vein thrombosis, and using non-selective beta-blockers or endoscopic therapy lowers risks of decompensation and improves tolerance to cancer therapies. TKI Hepatotoxicity: Sorafenib, lenvatinib, Cabozantinib, and regorafenib can cause reversible hepatocyte injury. Adverse events like transaminase or bilirubin elevation occur in 10–25%, with <1% mortality. ICI Hepatotoxicity: Immune checkpoint inhibitors (ICIs) bypass liver metabolism but may trigger immune-mediated hepatitis. Most cases resolve with corticosteroids, and low-grade events may correlate with better outcomes. Bleeding Risks: Anti-VEGF therapies (like bevacizumab) can cause variceal bleeding, though real-world rates are low (≈3%). Risk rises in patients with prior bleeds or macrovascular invasion. Potential Portal Pressure Benefit: Preclinical and pilot studies suggest VEGF blockade may reduce portal hypertension, but this remains experimental without large clinical validation. Sorafenib Data: The largest real-world registry (GIDEON) showed median OS of 5.2 months in Child-Pugh B versus 13.6 months in A. Adverse event rates were similar, but outcomes worsened with higher B scores. Other TKIs: Data for lenvatinib, regorafenib, and Cabozantinib in Child-Pugh B are limited. All confirm worse survival than in A patients but suggest possible modest benefit in carefully selected cases. Immunotherapy Evidence: CheckMate040 included Child-Pugh B patients, showing median OS of 7.6 months with nivolumab, with some patients improving from B to A after treatment response. Meta-Analyses: Pooled data confirm shorter survival in Child-Pugh B but show comparable safety and meaningful radiological responses (ORR ~14%, DCR ~46%), supporting cautious use. Comparative Studies: Retrospective cohorts suggest ICIs may provide better survival than TKIs or best supportive care (7.5 vs. 4 months). However, regional and selection biases limit generalizability. Decision Framework: Proposed algorithms suggest systemic therapy for B7 without ascites, possible therapy for B7 with ascites or B8 if recompensation potential exists, and best supportive care for B9 or unstable decompensation. Research Needs: Large prospective trials in Child-Pugh B are unlikely due to industry hesitancy, so real-world data, investigator-led studies, and biomarker-driven stratification are urgently needed to guide practice.gastroAGIDashboardDocumentsUpload DocumentsUsersUser ActivityRecent ChatSections ManageCustom QuestionsEmail TemplateConferenceGastroAGICirrhosis Liver2025NovemberClinical Challenge: Most pivotal HCC trials excluded Child-Pugh B patients, so systemic therapy in this group remains controversial. This leaves a large evidence gap for real-world decision-making. Guideline Variability: Western guidelines (AASLD, EASL, NCCN, ASCO, ESMO) differ in recommendations. Most endorse systemic therapy only in Child-Pugh A, with some cautiously allowing B7–B8 if performance status is good. Heterogeneity of Child-Pugh B: This class includes both compensated patients with mild biochemical abnormalities and decompensated patients with refractory ascites or encephalopathy. Prognosis varies widely within the subgroup. Survival Outcomes: Median overall survival drops dramatically: ~16 months in Child-Pugh A, ~6 months in Child-Pugh B, and <3 months in Child-Pugh C, underscoring the impact of liver dysfunction on prognosis. Alternative Assessments: Tools like ALBI grade and MELD score provide more objective measures of liver function, though they also have limitations. ALBI can stratify survival even within Child-Pugh A and B groups. Tumor-Related Dysfunction: Large tumors, macrovascular invasion, or necrosis can worsen liver function. In some cases, systemic therapy reducing tumor burden may improve hepatic reserve and allow “recompensation.” Cirrhosis-Related Dysfunction: Active viral hepatitis, alcohol use, or MASLD drive inflammation and decompensation. Managing these etiologies alongside systemic therapy is critical for patient stability. Recompensation Potential: Retrospective studies show recompensation in 12–56% of decompensated cirrhosis patients after etiological treatment (e.g., HBV antivirals, HCV DAAs, alcohol abstinence). This influences therapy eligibility. Portal Hypertension Management: Treating varices, portal vein thrombosis, and using non-selective beta-blockers or endoscopic therapy lowers risks of decompensation and improves tolerance to cancer therapies. TKI Hepatotoxicity: Sorafenib, lenvatinib, Cabozantinib, and regorafenib can cause reversible hepatocyte injury. Adverse events like transaminase or bilirubin elevation occur in 10–25%, with <1% mortality. ICI Hepatotoxicity: Immune checkpoint inhibitors (ICIs) bypass liver metabolism but may trigger immune-mediated hepatitis. Most cases resolve with corticosteroids, and low-grade events may correlate with better outcomes. Bleeding Risks: Anti-VEGF therapies (like bevacizumab) can cause variceal bleeding, though real-world rates are low (≈3%). Risk rises in patients with prior bleeds or macrovascular invasion. Potential Portal Pressure Benefit: Preclinical and pilot studies suggest VEGF blockade may reduce portal hypertension, but this remains experimental without large clinical validation. Sorafenib Data: The largest real-world registry (GIDEON) showed median OS of 5.2 months in Child-Pugh B versus 13.6 months in A. Adverse event rates were similar, but outcomes worsened with higher B scores. Other TKIs: Data for lenvatinib, regorafenib, and Cabozantinib in Child-Pugh B are limited. All confirm worse survival than in A patients but suggest possible modest benefit in carefully selected cases. Immunotherapy Evidence: CheckMate040 included Child-Pugh B patients, showing median OS of 7.6 months with nivolumab, with some patients improving from B to A after treatment response. Meta-Analyses: Pooled data confirm shorter survival in Child-Pugh B but show comparable safety and meaningful radiological responses (ORR ~14%, DCR ~46%), supporting cautious use. Comparative Studies: Retrospective cohorts suggest ICIs may provide better survival than TKIs or best supportive care (7.5 vs. 4 months). However, regional and selection biases limit generalizability. Decision Framework: Proposed algorithms suggest systemic therapy for B7 without ascites, possible therapy for B7 with ascites or B8 if recompensation potential exists, and best supportive care for B9 or unstable decompensation. Research Needs: Large prospective trials in Child-Pugh B are unlikely due to industry hesitancy, so real-world data, investigator-led studies, and biomarker-driven stratification are urgently needed to guide practice.ystemic therapy for hepatocellular carcinoma (HCC) in patients with advanced liver dysfunction (Child-Pugh class B) is a complex and controversial area of clinical management. This is primarily due to the exclusion of Child-Pugh B patients from most pivotal HCC clinical trials, leaving a substantial evidence gap for real-world decision-making. Below is an in-depth exploration of the key considerations, challenges, and available data regarding systemic therapies in this patient population. Key Challenges in Treating Child-Pugh B Patients Liver Dysfunction and Prognosis: Child-Pugh B heterogeneity: This group includes both compensated patients with mild biochemical abnormalities (e.g., B7) and decompensated patients with severe complications like refractory ascites or hepatic encephalopathy (e.g., B8–B9). Prognosis varies widely within the subgroup. Survival outcomes: Median overall survival (OS) drops significantly with worsening liver dysfunction: ~16 months for Child-Pugh A 6 months for Child-Pugh B <3 months for Child-Pugh C Guideline Variability: Western guidelines (AASLD, EASL, NCCN, ASCO, ESMO) generally recommend systemic therapy only for Child-Pugh A patients. Some guidelines cautiously allow systemic therapy for Child-Pugh B patients (specifically B7–B8) if their performance status is good and liver dysfunction is not severe. There is no consensus on how to approach systemic therapy for Child-Pugh B patients, reflecting the lack of robust trial data. Tumor-Related vs. Cirrhosis-Related Dysfunction: Tumor-related dysfunction: Large tumors, macrovascular invasion, or necrosis may exacerbate liver dysfunction. In some cases, systemic therapy that reduces tumor burden may improve hepatic reserve and allow "recompensation." Cirrhosis-related dysfunction: Active etiologies, such as viral hepatitis, alcohol use, or metabolic-associated steatotic liver disease (MASLD), drive inflammation and decompensation. Addressing these factors alongside systemic therapy is critical for patient stability. Available Systemic Therapies and Evidence in Child-Pugh B Tyrosine Kinase Inhibitors (TKIs): Sorafenib: The largest real-world registry (GIDEON) showed median OS of 5.2 months in Child-Pugh B versus 13.6 months in Child-Pugh A. Adverse event rates were similar between Child-Pugh A and B, but outcomes worsened with higher B scores. Sorafenib is generally considered for carefully selected Child-Pugh B7 patients with compensated liver function and good performance status. Lenvatinib, Regorafenib, Cabozantinib: Data for these TKIs in Child-Pugh B patients are limited. All confirm worse survival compared to Child-Pugh A patients but suggest modest benefit in carefully selected cases. Hepatotoxicity is a concern, with reversible transaminase or bilirubin elevations occurring in 10–25% of cases, though mortality rates are <1%. Immune Checkpoint Inhibitors (ICIs): Nivolumab: CheckMate040 trial included Child-Pugh B patients, showing a median OS of 7.6 months with nivolumab. Some patients improved from Child-Pugh B to A after treatment response, indicating potential for hepatic recompensation. ICIs bypass liver metabolism but can trigger immune-mediated hepatitis, which is typically manageable with corticosteroids. Comparative outcomes: Retrospective studies suggest ICIs may provide better survival than TKIs or best supportive care (7.5 months vs. 4 months, respectively). Meta-analyses show comparable safety and meaningful radiological responses in Child-Pugh B patients, with an objective response rate (ORR) of 14% and disease control rate (DCR) of 46%. Anti-VEGF Therapies: Bevacizumab (combined with atezolizumab): Anti-VEGF therapies can cause variceal bleeding, especially in patients with portal hypertension or prior bleeds, though real-world rates are low (3%). Pilot studies suggest VEGF blockade may reduce portal hypertension, but this remains experimental and requires further validation. Potential for Recompensation Recompensation Strategies: Retrospective studies show recompensation in 12–56% of decompensated cirrhosis patients after etiological treatment (e.g., HBV antivirals, HCV DAAs, alcohol abstinence). Managing portal hypertension (e.g., treating varices, portal vein thrombosis, using non-selective beta-blockers or endoscopic therapy) lowers risks of further decompensation and improves tolerance to cancer therapies. Impact on Therapy Eligibility: Patients who achieve recompensation may transition from Child-Pugh B to A, improving their eligibility for systemic therapy and prognosis. Decision Framework for Systemic Therapy in Child-Pugh B Proposed Algorithm: Child-Pugh B7: Without ascites: Systemic therapy may be considered, especially TKIs or ICIs. With ascites: Therapy may be cautiously attempted if recompensation potential exists. Child-Pugh B8: Therapy may be considered in select cases with stable decompensation and recompensation potential. Child-Pugh B9 or unstable decompensation: Best supportive care is generally recommended due to poor prognosis and inability to tolerate systemic therapy. Patient Selection: Careful selection based on performance status, liver dysfunction severity, and potential for hepatic recompensation is critical. Tools like ALBI grade and MELD score may provide more objective measures of liver function and help stratify survival within Child-Pugh B patients. Research Needs Real-World Data: Large prospective trials in Child-Pugh B patients are unlikely due to industry hesitancy. Therefore, real-world data, investigator-led studies, and biomarker-driven stratification are urgently needed to guide practice. Biomarker Development: Biomarkers predicting treatment response and hepatic recompensation potential could refine patient selection and improve outcomes. Comparative Studies: Head-to-head trials comparing ICIs, TKIs, and combination therapies specifically in Child-Pugh B patients are needed to establish optimal treatment strategies. Conclusion Systemic therapy in HCC patients with advanced liver dysfunction (Child-Pugh B) remains an area of significant clinical uncertainty. While TKIs like sorafenib and ICIs like nivolumab have shown modest benefits in carefully selected patients, the prognosis remains poor compared to Child-Pugh A patients. Managing underlying cirrhosis-related dysfunction, exploring recompensation strategies, and tailoring therapy based on performance status and liver function are essential. Continued research and real-world evidence are critical to addressing this unmet need.Generate AnswerUPDATE QUESTIONSrequestAnimationFrame(function(){RT=performance.now()});document.querySelectorAll('body link[rel="icon"], body link[rel="apple-touch-icon"]').forEach(el => document.head.appendChild(el))RB=[];RV=function(a){RT=performance.now();for(var b=0;b<a.length;b+=2){var c=a[b],e=a[b+1];null!==e.parentNode&&e.parentNode.removeChild(e);var f=c.parentNode;if(f){var g=c.previousSibling,h=0;do{if(c&&8===c.nodeType){var d=c.data;if("/"===d||"/&"===d)if(0===h)break;else h--;else""!==d&&"?"!==d&&""!==d&&"!"!==d&&"&"!==d||h++}d=c.nextSibling;f.removeChild(c);c=d}while(c);for(;e.firstChild;)f.insertBefore(e.firstChild,c);g.data="";g._reactRetry&&requestAnimationFrame(g._reactRetry)}}a.length=0}; RC=function(a,b){if(b=document.getElementById(b))(a=document.getElementById(a))?(a.previousSibling.data="",RB.push(a,b),2===RB.push(a,b),2===RB.push(a,b),2===RB.length&&("number"!==typeof RT?requestAnimationFrame(RT?requestAnimationFrame(RT?requestAnimationFrame(RV.bind(null,RB)):(a=performance.now(),setTimeout(RB)):(a=performance.now(),setTimeout(RB)):(a=performance.now(),setTimeout(RV.bind(null,RB),2300>a&&2E3<a?2300-a:RT+300-a)))):b.parentNode.removeChild(b)};RC("B:0","S:0")(self.__next_f=self.__next_f||[]).push([0])self.__next_f.push([1,"8:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/next-devtools/userspace/app/segment-explorer-node.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"SegmentViewNode"]\na:"Sreact.fragment"\n19:I["(app-pages-browser)/./src/lib/ReduxWrapper.tsx",["app/layout","static/chunks/app/layout.js"],"default"]\n1b:I["(app-pages-browser)/./src/lib/ValidateProvider.tsx",["app/layout","static/chunks/app/layout.js"],"default"]\n1d:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/layout-router.js",["app-pages-internals","static/chunks/app-pages-internals.js"],""]\n1f:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/render-from-template-context.js",["app-pages-internals","static/chunks/app-pages-internals.js"],""]\n3a:I["(app-pages-browser)/./src/features/route-guard/MainGuard.tsx",["app/(main)/layout","static/chunks/app/(main)/layout.js"],"default"]\n3c:I["(app-pages-browser)/./src/features/layouts/MainLayout/index.tsx",["app/(main)/layout","static/chunks/app/(main)/layout.js"],"default"]\n55:I["(app-pages-browser)/./src/features/main/custom-questions/CustomQuestions.tsx",["app/(main)/custom-questions/page","static/chunks/app/(main)/custom-questions/page.js"],"default"]\n58:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/lib/framework/boundary-components.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"OutletBoundary"]\n5f:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/metadata/async-metadata.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"AsyncMetadataOutlet"]\n67:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/"])self.__next_f.push([1,"node_modules/next/dist/lib/framework/boundary-components.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"ViewportBoundary"]\n6e:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/lib/framework/boundary-components.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"MetadataBoundary"]\n73:"Sreact.suspense"\n77:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/builtin/global-error.js",["app-pages-internals","static/chunks/app-pages-internals.js"],""]\n91:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/lib/metadata/generate/icon-mark.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"IconMark"]\n:HL["/_next/static/media/47cbc4e2adbc5db9-s.p.woff2","font",{"crossOrigin":"","type":"font/woff2"}]\n:HL["/_next/static/css/app/layout.css?v=1763968758666","style"]\n:HL["/_next/static/css/app/(main)/layout.css?v=1763968758666","style"]\n:HL["/_next/static/css/app/(main)/custom-questions/page.css?v=1763968758666","style"]\n:N1763968758668.999\n3:"EObject.defineProperty(()=\u003e{ctx.componentMod.preloadFont(href,type,ctx.renderOpts.crossOrigin,ctx.nonce)},"name",{value:""})"\n4:"EObject.defineProperty(()=\u003e{ctx.componentMod.preloadStyle(fullHref,ctx.renderOpts.crossOrigin,ctx.nonce)},"name",{value:""})"\n5:"EObject.defineProperty(()=\u003e{ctx.componentMod.preloadStyle(fullHref,ctx.renderOpts.crossOrigin,ctx.nonce)},"name",{value:""})"\n6:"EObject.defineProperty(()=\u003e{ctx.componentMod.preloadStyle(fullHref,ctx.renderOpts.crossOrigin,ctx.nonce)},"name",{value:""})"\n2:{"name":"Preloads","key":null,"env":"Server","stack":[],"props":{"preloadCallbacks":["3","4","5","6"]}}\n7:[]\n9:[]\nb:[["Array.map","",0,0,0,0,false]]\ne:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/clien"])self.__next_f.push([1,"t/components/layout-router.js",["app-pages-internals","static/chunks/app-pages-internals.js"],""]\n11:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/render-from-template-context.js",["app-pages-internals","static/chunks/app-pages-internals.js"],""]\n12:{}\n13:[["Function.all","",0,0,0,0,true]]\n10:{"children":["","L11",null,"12",null,"13",1]}\n14:[["Function.all","",0,0,0,0,true]]\nf:{"parallelRouterKey":"children","error":"undefined","errorStyles":"undefined","errorScripts":"undefined","template":["","a",null,"10",null,"14",0],"templateStyles":"undefined","templateScripts":"undefined","notFound":"Y","forbidden":"undefined","unauthorized":"undefined","segmentViewBoundaries":"Y"}\n15:[["Function.all","",0,0,0,0,true]]\nd:{"name":"RootLayout","key":null,"env":"Server","stack":[],"props":{"children":["","Le",null,"f",null,"15",1],"params":"Y"}}\n16:[["RootLayout","webpack-internal:///(rsc)/./src/app/layout.tsx",26,87,25,1,false]]\n17:[["RootLayout","webpack-internal:///(rsc)/./src/app/layout.tsx",29,94,25,1,false]]\n18:[["RootLayout","webpack-internal:///(rsc)/./src/app/layout.tsx",32,98,25,1,false]]\n1a:[["RootLayout","webpack-internal:///(rsc)/./src/app/layout.tsx",33,102,25,1,false]]\n1c:[["Function.all","",0,0,0,0,true]]\n1e:[["Function.all","",0,0,0,0,true]]\n20:[]\n22:{"name":"NotFound","key":null,"env":"Server","stack":[],"props":{}}\n23:{"name":"HTTPAccessErrorFallback","key":null,"env":"Server","owner":"22","stack":[],"props":{"status":404,"message":"This page could not be found."}}\n24:[]\n25:[]\n26:[]\n27:[]\n28:[]\n29:[]\n2a:[]\n2b:[["Function.all","",0,0,0,0,true]]\n2c:[["Function.all","",0,0,0,0,true]]\n2d:[["Function.all","",0,0,0,0,true]]\n2e:[["Function.all","",0,0,0,0,true]]\n2f:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n34:{}\n35:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n33:{"children":["","L1f",null,"34",null,"35",1]}\n36:[["Function.all","",0,0,0,0,true],["Func"])self.__next_f.push([1,"tion.all","",0,0,0,0,true]]\n32:{"parallelRouterKey":"children","error":"undefined","errorStyles":"undefined","errorScripts":"undefined","template":["","a",null,"33",null,"36",0],"templateStyles":"undefined","templateScripts":"undefined","notFound":"Y","forbidden":"undefined","unauthorized":"undefined","segmentViewBoundaries":"Y"}\n37:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n31:{"name":"Layout","key":null,"env":"Server","stack":[["Function.all","",0,0,0,0,true]],"props":{"children":["","L1d",null,"32",null,"37",1],"params":"Y"}}\n38:{"name":"LayoutWrapper","key":null,"env":"Server","owner":"31","stack":[["Layout","webpack-internal:///(rsc)/./src/app/(main)/layout.tsx",12,87,11,16,false]],"props":{"children":"31:props:children"}}\n39:[["LayoutWrapper","webpack-internal:///(rsc)/./src/features/layouts/index.tsx",37,95,19,98,false]]\n3b:[["LayoutWrapper","webpack-internal:///(rsc)/./src/features/layouts/index.tsx",38,102,19,98,false]]\n3d:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n3e:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n3f:[["Function.all","",0,0,0,0,true]]\n41:{"name":"NotFound","key":null,"env":"Server","stack":[["Function.all","",0,0,0,0,true]],"props":{}}\n42:{"name":"HTTPAccessErrorFallback","key":null,"env":"Server","owner":"41","stack":[],"props":{"status":404,"message":"This page could not be found."}}\n43:[]\n44:[]\n45:[]\n46:[]\n47:[]\n48:[]\n49:[]\n4a:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n4b:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n4c:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n4d:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n4e:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n4f:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n51:{"name":"page","key""])self.__next_f.push([1,":null,"env":"Server","stack":[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]],"props":{"params":"@52","searchParams":"@53"}}\n54:[["page","webpack-internal:///(rsc)/./src/app/(main)/custom-questions/page.tsx",12,87,11,14,false]]\n56:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n57:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n5b:"EObject.defineProperty(async function getViewportReady() {\n await viewport();\n return undefined;\n },"name",{value:"getViewportReady"})"\n5a:{"name":"next_outlet_boundary","key":null,"env":"Server","stack":[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]],"props":{"ready":"5b"}}\n5d:{"name":"StreamingMetadataOutletImpl","key":null,"env":"Server","stack":[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]],"props":{}}\n5e:[]\n61:[]\n63:{"name":"NonIndex","key":null,"env":"Server","stack":[],"props":{"pagePath":"/custom-questions","statusCode":200,"isPossibleServerAction":false}}\n65:{"name":"ViewportTree","key":null,"env":"Server","stack":[],"props":{}}\n66:[]\n69:{"name":"next_viewport_boundary","key":null,"env":"Server","owner":"65","stack":[],"props":{}}\n6a:[]\n6c:{"name":"MetadataTree","key":null,"env":"Server","stack":[],"props":{}}\n6d:[]\n70:{"name":"next_metadata_boundary","key":null,"env":"Server","owner":"6c","stack":[],"props":{}}\n71:[]\n72:[]\n75:{"name":"MetadataResolver","key":null,"env":"Server","owner":"70","stack":[],"props":{}}\n78:[]\n52:{}\n53:\n79:[]\n7a:[]\n7b:[]\n:W["warn","7b","5d","Server"," \u001b[33m\u001b[1m⚠\u001b[22m\u001b[39m Unsupported metadata themeColor is configured in metadata export in /custom-questions. Please move it to viewport export instead.\nRead more: https://nextjs.org/docs/app/api-reference/functions/generate-viewport"]\n7c:[]\n7d:[]\n7e"])self.__next_f.push([1,":[["Array.map","",0,0,0,0,false]]\n7f:[["Array.map","",0,0,0,0,false]]\n80:[]\n81:[]\n82:[]\n83:[]\n84:[]\n85:[]\n86:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n87:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n88:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n89:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n8a:[]\n8b:[]\n8c:[]\n8d:[]\n8e:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n8f:[["Array.map","",0,0,0,0,false]]\n90:[]\n1:D"2"\n1:null\nc:D"d"\n21:D"22"\n21:D"23"\n"])self.__next_f.push([1,"21:[["","title",null,{"children":"404: This page could not be found."},"23","24",1],["","div",null,{"style":{"fontFamily":"system-ui,"Segoe UI",Roboto,Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji"","height":"100vh","textAlign":"center","display":"flex","flexDirection":"column","alignItems":"center","justifyContent":"center"},"children":["","div",null,{"children":[["","style",null,{"dangerouslySetInnerHTML":{"__html":"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}"}},"23","27",1],["","h1",null,{"className":"next-error-h1","style":{"display":"inline-block","margin":"0 20px 0 0","padding":"0 23px 0 0","fontSize":24,"fontWeight":500,"verticalAlign":"top","lineHeight":"49px"},"children":404},"23","28",1],["","div",null,{"style":{"display":"inline-block"},"children":["","h2",null,{"style":{"fontSize":14,"fontWeight":400,"lineHeight":"49px","margin":0},"children":"This page could not be found."},"23","2a",1]},"23","29",1]]},"23","26",1]},"23","25",1]]\n"])self.__next_f.push([1,"c:["","html",null,{"lang":"en","className":"w-[100dvw] h-[100dvh]","children":["","body",null,{"id":"body","className":"__variable_372368 antialiased font-sans bg-white ","children":["","L19",null,{"children":["","L1b",null,{"children":["","L1d",null,{"parallelRouterKey":"children","error":"undefined","errorStyles":"undefined","errorScripts":"undefined","template":["","L1f",null,{},null,"1e",1],"templateStyles":"undefined","templateScripts":"undefined","notFound":["","L8","c-not-found",{"type":"not-found","pagePath":"__next_builtin__not-found.js","children":["21",[]]},null,"20",0],"forbidden":"undefined","unauthorized":"undefined","segmentViewBoundaries":[["","L8",null,{"type":"boundary:not-found","pagePath":"__next_builtin__not-found.js@boundary"},null,"2b",1],"undefined","undefined",["","L8",null,{"type":"boundary:global-error","pagePath":"__next_builtin__global-error.js"},null,"2c",1]]},null,"1c",1]},"d","1a",1]},"d","18",1]},"d","17",1]},"d","16",1]\n"])self.__next_f.push([1,"30:D"31"\n30:D"38"\n40:D"41"\n40:D"42"\n"])self.__next_f.push([1,"40:[["","title",null,{"children":"404: This page could not be found."},"42","43",1],["","div",null,{"style":"21:1:props:style","children":["","div",null,{"children":[["","style",null,{"dangerouslySetInnerHTML":{"__html":"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}"}},"42","46",1],["","h1",null,{"className":"next-error-h1","style":"21:1:props:children:props:children:1:props:style","children":404},"42","47",1],["","div",null,{"style":"21:1:props:children:props:children:2:props:style","children":["","h2",null,{"style":"21:1:props:children:props:children:2:props:children:props:style","children":"This page could not be found."},"42","49",1]},"42","48",1]]},"42","45",1]},"42","44",1]]\n"])self.__next_f.push([1,"30:["","L3a",null,{"children":["","L3c",null,{"children":["","L1d",null,{"parallelRouterKey":"children","error":"undefined","errorStyles":"undefined","errorScripts":"undefined","template":["","L1f",null,{},null,"3e",1],"templateStyles":"undefined","templateScripts":"undefined","notFound":["","L8","c-not-found",{"type":"not-found","pagePath":"__next_builtin__not-found.js","children":["40",[]]},null,"3f",0],"forbidden":"undefined","unauthorized":"undefined","segmentViewBoundaries":[["","L8",null,{"type":"boundary:not-found","pagePath":"__next_builtin__not-found.js@boundary"},null,"4a",1],"undefined","undefined","undefined"]},null,"3d",1]},"38","3b",1]},"38","39",1]\n"])self.__next_f.push([1,"50:D"51"\n50:["","L55",null,{},"51","54",1]\n59:D"5a"\n5c:D"5d"\n5c:["","L5f",null,{"promise":"@60"},"5d","5e",1]\n62:D"63"\n62:null\n64:D"65"\n68:D"69"\n64:[["","L67",null,{"children":"L68"},"65","66",1],["","meta",null,{"name":"next-size-adjust","content":""},"65","6a",1]]\n6b:D"6c"\n6f:D"70"\n74:D"75"\n6f:["","div",null,{"hidden":true,"children":["","73",null,{"fallback":null,"children":"L74"},"70","72",1]},"70","71",1]\n6b:["","L6e",null,{"children":"6f"},"6c","6d",1]\n76:[]\n"])self.__next_f.push([1,"0:{"P":"1","b":"development","p":"","c":["","custom-questions?question=b66bcd26-e38e-4699-b668-62581e13ca68"],"i":false,"f":[[["",{"children":["(main)",{"children":["custom-questions",{"children":["PAGE?{"question":"b66bcd26-e38e-4699-b668-62581e13ca68"}",{}]}]}]},"undefined","undefined",true],["",["","L8","layout",{"type":"layout","pagePath":"layout.tsx","children":["","a","c",{"children":[[["","link","0",{"rel":"stylesheet","href":"/_next/static/css/app/layout.css?v=1763968758666","precedence":"next_static/css/app/layout.css","crossOrigin":"undefined","nonce":"undefined"},null,"b",0]],"c"]},null,"9",1]},null,"7",0],{"children":["(main)",["","L8","layout",{"type":"layout","pagePath":"(main)/layout.tsx","children":["","a","c",{"children":[[["","link","0",{"rel":"stylesheet","href":"/_next/static/css/app/(main)/layout.css?v=1763968758666","precedence":"next_static/css/app/(main)/layout.css","crossOrigin":"undefined","nonce":"undefined"},null,"2f",0]],"30"]},null,"2e",1]},null,"2d",0],{"children":["custom-questions",["","a","c",{"children":[null,["","L1d",null,{"parallelRouterKey":"children","error":"undefined","errorStyles":"undefined","errorScripts":"undefined","template":["","L1f",null,{},null,"4d",1],"templateStyles":"undefined","templateScripts":"undefined","notFound":"undefined","forbidden":"undefined","unauthorized":"undefined","segmentViewBoundaries":["undefined","undefined","undefined","undefined"]},null,"4c",1]]},null,"4b",0],{"children":["PAGE",["","a","c",{"children":[["","L8","c-page",{"type":"page","pagePath":"(main)/custom-questions/page.tsx","children":"50"},null,"4f",1],[["","link","0",{"rel":"stylesheet","href":"/_next/static/css/app/(main)/custom-questions/page.css?v=1763968758666","precedence":"next_static/css/app/(main)/custom-questions/page.css","crossOrigin":"undefined","nonce":"undefined"},null,"56",0]],["","L58",null,{"children":["L59","5c"]},null,"57",1]]},null,"4e",0],{},null,false]},null,false]},null,false]},null,false],["","a","h",{"children":["62","64","6b"]},null,"61",0],false]],"m":"W76","G":["77",["","L8","ge-svn",{"type":"global-error","pagePath":"__next_builtin__global-error.js","children":[]},null,"78",0]],"s":false,"S":false}\n"])self.__next_f.push([1,"68:[["","meta","0",{"charSet":"utf-8"},"5a","79",0],["","meta","1",{"name":"viewport","content":"width=device-width, initial-scale=1"},"5a","7a",0]]\n59:null\n"])self.__next_f.push([1,"60:{"metadata":[["","title","0",{"children":"Admin Panel | GastroAGI"},"5d","7c",0],["","meta","1",{"name":"description","content":"Manage GastroAGI content, users, and configurations through the Admin Panel."},"5d","7d",0],["","link","2",{"rel":"author","href":"https://gastroagi.com"},"5d","7e",0],["","meta","3",{"name":"author","content":"GastroAGI Team"},"5d","7f",0],["","meta","4",{"name":"keywords","content":"GastroAGI Admin,Gastroenterology Dashboard,GastroAGI Management,Gastro AGI Backend,Admin Panel GastroAGI,Medical AI Admin,GastroAI Tools Admin"},"5d","80",0],["","meta","5",{"name":"creator","content":"GastroAGI Team"},"5d","81",0],["","meta","6",{"property":"og:title","content":"Admin Panel | GastroAGI"},"5d","82",0],["","meta","7",{"property":"og:description","content":"Manage GastroAGI content, users, and configurations through the Admin Panel."},"5d","83",0],["","meta","8",{"property":"og:url","content":"https://gastroagi.com/admin"},"5d","84",0],["","meta","9",{"property":"og:site_name","content":"GastroAGI Admin"},"5d","85",0],["","meta","10",{"property":"og:image:type","content":"image/jpeg"},"5d","86",0],["","meta","11",{"property":"og:image:width","content":"5472"},"5d","87",0],["","meta","12",{"property":"og:image:height","content":"3648"},"5d","88",0],["","meta","13",{"property":"og:image","content":"http://localhost:5454/opengraph-image.jpg?7d84d2c790da1724"},"5d","89",0],["","meta","14",{"property":"og:type","content":"website"},"5d","8a",0],["","meta","15",{"name":"twitter:card","content":"summary_large_image"},"5d","8b",0],["","meta","16",{"name":"twitter:title","content":"Admin Panel | GastroAGI"},"5d","8c",0],["","meta","17",{"name":"twitter:description","content":"Manage GastroAGI content, users, and configurations through the Admin Panel."},"5d","8d",0],["","meta","18",{"name":"twitter:image","content":"https://gastroagi.com/admin-og-image.png"},"5d","8e",0],["","link","19",{"rel":"icon","href":"/favicon.ico","type":"image/x-icon","sizes":"1829x2523"},"5d","8f",0],["","L91","20",{},"5d","90",0]],"error":null,"digest":"undefined"}\n"])self.__next_f.push([1,"74:"60:metadata"\n"])Generate AnswerUPDATE QUESTIONSrequestAnimationFrame(function(){RT=performance.now()});document.querySelectorAll('body link[rel="icon"], body link[rel="apple-touch-icon"]').forEach(el => document.head.appendChild(el))RB=[];RV=function(a){RT=performance.now();for(var b=0;b<a.length;b+=2){var c=a[b],e=a[b+1];null!==e.parentNode&&e.parentNode.removeChild(e);var f=c.parentNode;if(f){var g=c.previousSibling,h=0;do{if(c&&8===c.nodeType){var d=c.data;if("/"===d||"/&"===d)if(0===h)break;else h--;else""!==d&&"?"!==d&&""!==d&&"!"!==d&&"&"!==d||h++}d=c.nextSibling;f.removeChild(c);c=d}while(c);for(;e.firstChild;)f.insertBefore(e.firstChild,c);g.data="";g._reactRetry&&requestAnimationFrame(g._reactRetry)}}a.length=0}; RC=function(a,b){if(b=document.getElementById(b))(a=document.getElementById(a))?(a.previousSibling.data="",RB.push(a,b),2===RB.push(a,b),2===RB.push(a,b),2===RB.length&&("number"!==typeof RT?requestAnimationFrame(RT?requestAnimationFrame(RT?requestAnimationFrame(RV.bind(null,RB)):(a=performance.now(),setTimeout(RB)):(a=performance.now(),setTimeout(RB)):(a=performance.now(),setTimeout(RV.bind(null,RB),2300>a&&2E3<a?2300-a:RT+300-a)))):b.parentNode.removeChild(b)};RC("B:0","S:0")(self.__next_f=self.__next_f||[]).push([0])self.__next_f.push([1,"8:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/next-devtools/userspace/app/segment-explorer-node.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"SegmentViewNode"]\na:"Sreact.fragment"\n19:I["(app-pages-browser)/./src/lib/ReduxWrapper.tsx",["app/layout","static/chunks/app/layout.js"],"default"]\n1b:I["(app-pages-browser)/./src/lib/ValidateProvider.tsx",["app/layout","static/chunks/app/layout.js"],"default"]\n1d:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/layout-router.js",["app-pages-internals","static/chunks/app-pages-internals.js"],""]\n1f:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/render-from-template-context.js",["app-pages-internals","static/chunks/app-pages-internals.js"],""]\n3a:I["(app-pages-browser)/./src/features/route-guard/MainGuard.tsx",["app/(main)/layout","static/chunks/app/(main)/layout.js"],"default"]\n3c:I["(app-pages-browser)/./src/features/layouts/MainLayout/index.tsx",["app/(main)/layout","static/chunks/app/(main)/layout.js"],"default"]\n55:I["(app-pages-browser)/./src/features/main/sections/Sections.tsx",["app/(main)/sections/page","static/chunks/app/(main)/sections/page.js"],"default"]\n58:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/lib/framework/boundary-components.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"OutletBoundary"]\n5f:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/metadata/async-metadata.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"AsyncMetadataOutlet"]\n67:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/lib/fram"])self.__next_f.push([1,"ework/boundary-components.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"ViewportBoundary"]\n6e:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/lib/framework/boundary-components.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"MetadataBoundary"]\n73:"Sreact.suspense"\n77:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/builtin/global-error.js",["app-pages-internals","static/chunks/app-pages-internals.js"],""]\n91:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/lib/metadata/generate/icon-mark.js",["app-pages-internals","static/chunks/app-pages-internals.js"],"IconMark"]\n:HL["/_next/static/media/47cbc4e2adbc5db9-s.p.woff2","font",{"crossOrigin":"","type":"font/woff2"}]\n:HL["/_next/static/css/app/layout.css?v=1763968824704","style"]\n:HL["/_next/static/css/app/(main)/layout.css?v=1763968824704","style"]\n:HL["/_next/static/css/app/(main)/sections/page.css?v=1763968824704","style"]\n:N1763968824725.5613\n3:"EObject.defineProperty(()=\u003e{ctx.componentMod.preloadFont(href,type,ctx.renderOpts.crossOrigin,ctx.nonce)},"name",{value:""})"\n4:"EObject.defineProperty(()=\u003e{ctx.componentMod.preloadStyle(fullHref,ctx.renderOpts.crossOrigin,ctx.nonce)},"name",{value:""})"\n5:"EObject.defineProperty(()=\u003e{ctx.componentMod.preloadStyle(fullHref,ctx.renderOpts.crossOrigin,ctx.nonce)},"name",{value:""})"\n6:"EObject.defineProperty(()=\u003e{ctx.componentMod.preloadStyle(fullHref,ctx.renderOpts.crossOrigin,ctx.nonce)},"name",{value:""})"\n2:{"name":"Preloads","key":null,"env":"Server","stack":[],"props":{"preloadCallbacks":["3","4","5","6"]}}\n7:[]\n9:[]\nb:[["Array.map","",0,0,0,0,false]]\ne:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/layout-router.js",["app-p"])self.__next_f.push([1,"ages-internals","static/chunks/app-pages-internals.js"],""]\n11:I["(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/render-from-template-context.js",["app-pages-internals","static/chunks/app-pages-internals.js"],""]\n12:{}\n13:[["Function.all","",0,0,0,0,true]]\n10:{"children":["","L11",null,"12",null,"13",1]}\n14:[["Function.all","",0,0,0,0,true]]\nf:{"parallelRouterKey":"children","error":"undefined","errorStyles":"undefined","errorScripts":"undefined","template":["","a",null,"10",null,"14",0],"templateStyles":"undefined","templateScripts":"undefined","notFound":"Y","forbidden":"undefined","unauthorized":"undefined","segmentViewBoundaries":"Y"}\n15:[["Function.all","",0,0,0,0,true]]\nd:{"name":"RootLayout","key":null,"env":"Server","stack":[],"props":{"children":["","Le",null,"f",null,"15",1],"params":"Y"}}\n16:[["RootLayout","webpack-internal:///(rsc)/./src/app/layout.tsx",26,87,25,1,false]]\n17:[["RootLayout","webpack-internal:///(rsc)/./src/app/layout.tsx",29,94,25,1,false]]\n18:[["RootLayout","webpack-internal:///(rsc)/./src/app/layout.tsx",32,98,25,1,false]]\n1a:[["RootLayout","webpack-internal:///(rsc)/./src/app/layout.tsx",33,102,25,1,false]]\n1c:[["Function.all","",0,0,0,0,true]]\n1e:[["Function.all","",0,0,0,0,true]]\n20:[]\n22:{"name":"NotFound","key":null,"env":"Server","stack":[],"props":{}}\n23:{"name":"HTTPAccessErrorFallback","key":null,"env":"Server","owner":"22","stack":[],"props":{"status":404,"message":"This page could not be found."}}\n24:[]\n25:[]\n26:[]\n27:[]\n28:[]\n29:[]\n2a:[]\n2b:[["Function.all","",0,0,0,0,true]]\n2c:[["Function.all","",0,0,0,0,true]]\n2d:[["Function.all","",0,0,0,0,true]]\n2e:[["Function.all","",0,0,0,0,true]]\n2f:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n34:{}\n35:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n33:{"children":["","L1f",null,"34",null,"35",1]}\n36:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n32:{"paral"])self.__next_f.push([1,"lelRouterKey":"children","error":"undefined","errorStyles":"undefined","errorScripts":"undefined","template":["","a",null,"33",null,"36",0],"templateStyles":"undefined","templateScripts":"undefined","notFound":"Y","forbidden":"undefined","unauthorized":"undefined","segmentViewBoundaries":"Y"}\n37:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n31:{"name":"Layout","key":null,"env":"Server","stack":[["Function.all","",0,0,0,0,true]],"props":{"children":["","L1d",null,"32",null,"37",1],"params":"Y"}}\n38:{"name":"LayoutWrapper","key":null,"env":"Server","owner":"31","stack":[["Layout","webpack-internal:///(rsc)/./src/app/(main)/layout.tsx",12,87,11,16,false]],"props":{"children":"31:props:children"}}\n39:[["LayoutWrapper","webpack-internal:///(rsc)/./src/features/layouts/index.tsx",37,95,19,98,false]]\n3b:[["LayoutWrapper","webpack-internal:///(rsc)/./src/features/layouts/index.tsx",38,102,19,98,false]]\n3d:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n3e:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n3f:[["Function.all","",0,0,0,0,true]]\n41:{"name":"NotFound","key":null,"env":"Server","stack":[["Function.all","",0,0,0,0,true]],"props":{}}\n42:{"name":"HTTPAccessErrorFallback","key":null,"env":"Server","owner":"41","stack":[],"props":{"status":404,"message":"This page could not be found."}}\n43:[]\n44:[]\n45:[]\n46:[]\n47:[]\n48:[]\n49:[]\n4a:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n4b:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n4c:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n4d:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n4e:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n4f:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n51:{"name":"page","key":null,"env":"Server","stack":[["Functi"])self.__next_f.push([1,"on.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]],"props":{"params":"@52","searchParams":"@53"}}\n54:[["page","webpack-internal:///(rsc)/./src/app/(main)/sections/page.tsx",14,87,13,14,false]]\n56:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n57:[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]]\n5b:"EObject.defineProperty(async function getViewportReady() {\n await viewport();\n return undefined;\n },"name",{value:"getViewportReady"})"\n5a:{"name":"next_outlet_boundary","key":null,"env":"Server","stack":[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]],"props":{"ready":"5b"}}\n5d:{"name":"StreamingMetadataOutletImpl","key":null,"env":"Server","stack":[["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true],["Function.all","",0,0,0,0,true]],"props":{}}\n5e:[]\n61:[]\n63:{"name":"NonIndex","key":null,"env":"Server","stack":[],"props":{"pagePath":"/sections","statusCode":200,"isPossibleServerAction":false}}\n65:{"name":"ViewportTree","key":null,"env":"Server","stack":[],"props":{}}\n66:[]\n69:{"name":"next_viewport_boundary","key":null,"env":"Server","owner":"65","stack":[],"props":{}}\n6a:[]\n6c:{"name":"MetadataTree","key":null,"env":"Server","stack":[],"props":{}}\n6d:[]\n70:{"name":"next_metadata_boundary","key":null,"env":"Server","owner":"6c","stack":[],"props":{}}\n71:[]\n72:[]\n75:{"name":"MetadataResolver","key":null,"env":"Server","owner":"70","stack":[],"props":{}}\n78:[]\n52:{}\n53:\n79:[]\n7a:[]\n7b:[]\n:W["warn","7b","5d","Server"," \u001b[33m\u001b[1m⚠\u001b[22m\u001b[39m Unsupported metadata themeColor is configured in metadata export in /sections. Please move it to viewport export instead.\nRead more: https://nextjs.org/docs/app/api-reference/functions/generate-viewport"]\n7c:[]\n7d:[]\n7e:[["Array.map","",0,0,0,0,false]]\n7f:[["Array.map","",0,0,0,0,"])self.__next_f.push([1,"false]]\n80:[]\n81:[]\n82:[]\n83:[]\n84:[]\n85:[]\n86:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n87:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n88:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n89:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n8a:[]\n8b:[]\n8c:[]\n8d:[]\n8e:[["Array.map","",0,0,0,0,false],["Array.map","",0,0,0,0,false]]\n8f:[["Array.map","",0,0,0,0,false]]\n90:[]\n1:D"2"\n1:null\nc:D"d"\n21:D"22"\n21:D"23"\n"])self.__next_f.push([1,"21:[["","title",null,{"children":"404: This page could not be found."},"23","24",1],["","div",null,{"style":{"fontFamily":"system-ui,"Segoe UI",Roboto,Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji"","height":"100vh","textAlign":"center","display":"flex","flexDirection":"column","alignItems":"center","justifyContent":"center"},"children":["","div",null,{"children":[["","style",null,{"dangerouslySetInnerHTML":{"__html":"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}"}},"23","27",1],["","h1",null,{"className":"next-error-h1","style":{"display":"inline-block","margin":"0 20px 0 0","padding":"0 23px 0 0","fontSize":24,"fontWeight":500,"verticalAlign":"top","lineHeight":"49px"},"children":404},"23","28",1],["","div",null,{"style":{"display":"inline-block"},"children":["","h2",null,{"style":{"fontSize":14,"fontWeight":400,"lineHeight":"49px","margin":0},"children":"This page could not be found."},"23","2a",1]},"23","29",1]]},"23","26",1]},"23","25",1]]\n"])self.__next_f.push([1,"c:["","html",null,{"lang":"en","className":"w-[100dvw] h-[100dvh]","children":["","body",null,{"id":"body","className":"__variable_372368 antialiased font-sans bg-white ","children":["","L19",null,{"children":["","L1b",null,{"children":["","L1d",null,{"parallelRouterKey":"children","error":"undefined","errorStyles":"undefined","errorScripts":"undefined","template":["","L1f",null,{},null,"1e",1],"templateStyles":"undefined","templateScripts":"undefined","notFound":["","L8","c-not-found",{"type":"not-found","pagePath":"__next_builtin__not-found.js","children":["21",[]]},null,"20",0],"forbidden":"undefined","unauthorized":"undefined","segmentViewBoundaries":[["","L8",null,{"type":"boundary:not-found","pagePath":"__next_builtin__not-found.js@boundary"},null,"2b",1],"undefined","undefined",["","L8",null,{"type":"boundary:global-error","pagePath":"__next_builtin__global-error.js"},null,"2c",1]]},null,"1c",1]},"d","1a",1]},"d","18",1]},"d","17",1]},"d","16",1]\n"])self.__next_f.push([1,"30:D"31"\n30:D"38"\n40:D"41"\n40:D"42"\n"])self.__next_f.push([1,"40:[["","title",null,{"children":"404: This page could not be found."},"42","43",1],["","div",null,{"style":"21:1:props:style","children":["","div",null,{"children":[["","style",null,{"dangerouslySetInnerHTML":{"__html":"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}"}},"42","46",1],["","h1",null,{"className":"next-error-h1","style":"21:1:props:children:props:children:1:props:style","children":404},"42","47",1],["","div",null,{"style":"21:1:props:children:props:children:2:props:style","children":["","h2",null,{"style":"21:1:props:children:props:children:2:props:children:props:style","children":"This page could not be found."},"42","49",1]},"42","48",1]]},"42","45",1]},"42","44",1]]\n"])self.__next_f.push([1,"30:["","L3a",null,{"children":["","L3c",null,{"children":["","L1d",null,{"parallelRouterKey":"children","error":"undefined","errorStyles":"undefined","errorScripts":"undefined","template":["","L1f",null,{},null,"3e",1],"templateStyles":"undefined","templateScripts":"undefined","notFound":["","L8","c-not-found",{"type":"not-found","pagePath":"__next_builtin__not-found.js","children":["40",[]]},null,"3f",0],"forbidden":"undefined","unauthorized":"undefined","segmentViewBoundaries":[["","L8",null,{"type":"boundary:not-found","pagePath":"__next_builtin__not-found.js@boundary"},null,"4a",1],"undefined","undefined","undefined"]},null,"3d",1]},"38","3b",1]},"38","39",1]\n"])self.__next_f.push([1,"50:D"51"\n50:["","L55",null,{},"51","54",1]\n59:D"5a"\n5c:D"5d"\n5c:["","L5f",null,{"promise":"@60"},"5d","5e",1]\n62:D"63"\n62:null\n64:D"65"\n68:D"69"\n64:[["","L67",null,{"children":"L68"},"65","66",1],["","meta",null,{"name":"next-size-adjust","content":""},"65","6a",1]]\n6b:D"6c"\n6f:D"70"\n74:D"75"\n6f:["","div",null,{"hidden":true,"children":["","73",null,{"fallback":null,"children":"L74"},"70","72",1]},"70","71",1]\n6b:["","L6e",null,{"children":"6f"},"6c","6d",1]\n76:[]\n"])self.__next_f.push([1,"0:{"P":"1","b":"development","p":"","c":["","sections"],"i":false,"f":[[["",{"children":["(main)",{"children":["sections",{"children":["PAGE",{}]}]}]},"undefined","undefined",true],["",["","L8","layout",{"type":"layout","pagePath":"layout.tsx","children":["","a","c",{"children":[[["","link","0",{"rel":"stylesheet","href":"/_next/static/css/app/layout.css?v=1763968824704","precedence":"next_static/css/app/layout.css","crossOrigin":"undefined","nonce":"undefined"},null,"b",0]],"c"]},null,"9",1]},null,"7",0],{"children":["(main)",["","L8","layout",{"type":"layout","pagePath":"(main)/layout.tsx","children":["","a","c",{"children":[[["","link","0",{"rel":"stylesheet","href":"/_next/static/css/app/(main)/layout.css?v=1763968824704","precedence":"next_static/css/app/(main)/layout.css","crossOrigin":"undefined","nonce":"undefined"},null,"2f",0]],"30"]},null,"2e",1]},null,"2d",0],{"children":["sections",["","a","c",{"children":[null,["","L1d",null,{"parallelRouterKey":"children","error":"undefined","errorStyles":"undefined","errorScripts":"undefined","template":["","L1f",null,{},null,"4d",1],"templateStyles":"undefined","templateScripts":"undefined","notFound":"undefined","forbidden":"undefined","unauthorized":"undefined","segmentViewBoundaries":["undefined","undefined","undefined","undefined"]},null,"4c",1]]},null,"4b",0],{"children":["PAGE",["","a","c",{"children":[["","L8","c-page",{"type":"page","pagePath":"(main)/sections/page.tsx","children":"50"},null,"4f",1],[["","link","0",{"rel":"stylesheet","href":"/_next/static/css/app/(main)/sections/page.css?v=1763968824704","precedence":"next_static/css/app/(main)/sections/page.css","crossOrigin":"undefined","nonce":"undefined"},null,"56",0]],["","L58",null,{"children":["L59","5c"]},null,"57",1]]},null,"4e",0],{},null,false]},null,false]},null,false]},null,false],["","a","h",{"children":["62","64","6b"]},null,"61",0],false]],"m":"W76","G":["77",["","L8","ge-svn",{"type":"global-error","pagePath":"__next_builtin__global-error.js","children":[]},null,"78",0]],"s":false,"S":false}\n"])self.__next_f.push([1,"68:[["","meta","0",{"charSet":"utf-8"},"5a","79",0],["","meta","1",{"name":"viewport","content":"width=device-width, initial-scale=1"},"5a","7a",0]]\n59:null\n"])self.__next_f.push([1,"60:{"metadata":[["","title","0",{"children":"Admin Panel | GastroAGI"},"5d","7c",0],["","meta","1",{"name":"description","content":"Manage GastroAGI content, users, and configurations through the Admin Panel."},"5d","7d",0],["","link","2",{"rel":"author","href":"https://gastroagi.com"},"5d","7e",0],["","meta","3",{"name":"author","content":"GastroAGI Team"},"5d","7f",0],["","meta","4",{"name":"keywords","content":"GastroAGI Admin,Gastroenterology Dashboard,GastroAGI Management,Gastro AGI Backend,Admin Panel GastroAGI,Medical AI Admin,GastroAI Tools Admin"},"5d","80",0],["","meta","5",{"name":"creator","content":"GastroAGI Team"},"5d","81",0],["","meta","6",{"property":"og:title","content":"Admin Panel | GastroAGI"},"5d","82",0],["","meta","7",{"property":"og:description","content":"Manage GastroAGI content, users, and configurations through the Admin Panel."},"5d","83",0],["","meta","8",{"property":"og:url","content":"https://gastroagi.com/admin"},"5d","84",0],["","meta","9",{"property":"og:site_name","content":"GastroAGI Admin"},"5d","85",0],["","meta","10",{"property":"og:image:type","content":"image/jpeg"},"5d","86",0],["","meta","11",{"property":"og:image:width","content":"5472"},"5d","87",0],["","meta","12",{"property":"og:image:height","content":"3648"},"5d","88",0],["","meta","13",{"property":"og:image","content":"http://localhost:5454/opengraph-image.jpg?7d84d2c790da1724"},"5d","89",0],["","meta","14",{"property":"og:type","content":"website"},"5d","8a",0],["","meta","15",{"name":"twitter:card","content":"summary_large_image"},"5d","8b",0],["","meta","16",{"name":"twitter:title","content":"Admin Panel | GastroAGI"},"5d","8c",0],["","meta","17",{"name":"twitter:description","content":"Manage GastroAGI content, users, and configurations through the Admin Panel."},"5d","8d",0],["","meta","18",{"name":"twitter:image","content":"https://gastroagi.com/admin-og-image.png"},"5d","8e",0],["","link","19",{"rel":"icon","href":"/favicon.ico","type":"image/x-icon","sizes":"1829x2523"},"5d","8f",0],["","L91","20",{},"5d","90",0]],"error":null,"digest":"undefined"}\n"])self.__next_f.push([1,"74:"60:metadata"\n"])Generate AnswerUPDATE QUESTIONSrequestAnimationFrame(function(){$RT=performance.now()});document.querySelectorAll('body link[rel="icon"], body link[rel="apple-touch-icon"]').forEach(el => document.head.appendChild(el))$RB=[];$RV=function(a){$RT=performance.now();for(var b=0;b<a.length;b+=2){var c=a[b],e=a[b+1];null!==e.parentNode&&e.parentNode.removeChild(e);var f=c.parentNode;if(f){var g=c.previousSibling,h=0;do{if(c&&8===c.nodeType){var d=c.data;if("/$"===d||"/&"===d)if(0===h)break;else h--;else"$"!==d&&"$?"!==d&&"$~"!==d&&"$!"!==d&&"&"!==d||h++}d=c.nextSibling;f.removeChild(c);c=d}while(c);for(;e.firstChild;)f.insertBefore(e.firstChild,c);g.data="$";g._reactRetry&&requestAnimationFrame(g._reactRetry)}}a.length=0}; $RC=function(a,b){if(b=document.getElementById(b))(a=document.getElementById(a))?(a.previousSibling.data="$~",$RB.push(a,b),2===$RB.length&&("number"!==typeof $RT?requestAnimationFrame($RV.bind(null,$RB)):(a=performance.now(),setTimeout($RV.bind(null,$RB),2300>a&&2E3<a?2300-a:$RT+300-a)))):b.parentNode.removeChild(b)};$RC("B:0","S:0")(self.__next_f=self.__next_f||[]).push([0])self.__next_f.push([1,"8:I[\"(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/next-devtools/userspace/app/segment-explorer-node.js\",[\"app-pages-internals\",\"static/chunks/app-pages-internals.js\"],\"SegmentViewNode\"]\na:\"$Sreact.fragment\"\n19:I[\"(app-pages-browser)/./src/lib/ReduxWrapper.tsx\",[\"app/layout\",\"static/chunks/app/layout.js\"],\"default\"]\n1b:I[\"(app-pages-browser)/./src/lib/ValidateProvider.tsx\",[\"app/layout\",\"static/chunks/app/layout.js\"],\"default\"]\n1d:I[\"(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/layout-router.js\",[\"app-pages-internals\",\"static/chunks/app-pages-internals.js\"],\"\"]\n1f:I[\"(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/render-from-template-context.js\",[\"app-pages-internals\",\"static/chunks/app-pages-internals.js\"],\"\"]\n3a:I[\"(app-pages-browser)/./src/features/route-guard/MainGuard.tsx\",[\"app/(main)/layout\",\"static/chunks/app/(main)/layout.js\"],\"default\"]\n3c:I[\"(app-pages-browser)/./src/features/layouts/MainLayout/index.tsx\",[\"app/(main)/layout\",\"static/chunks/app/(main)/layout.js\"],\"default\"]\n55:I[\"(app-pages-browser)/./src/features/main/sections/Sections.tsx\",[\"app/(main)/sections/page\",\"static/chunks/app/(main)/sections/page.js\"],\"default\"]\n58:I[\"(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/lib/framework/boundary-components.js\",[\"app-pages-internals\",\"static/chunks/app-pages-internals.js\"],\"OutletBoundary\"]\n5f:I[\"(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/metadata/async-metadata.js\",[\"app-pages-internals\",\"static/chunks/app-pages-internals.js\"],\"AsyncMetadataOutlet\"]\n67:I[\"(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/lib/fram"])self.__next_f.push([1,"ework/boundary-components.js\",[\"app-pages-internals\",\"static/chunks/app-pages-internals.js\"],\"ViewportBoundary\"]\n6e:I[\"(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/lib/framework/boundary-components.js\",[\"app-pages-internals\",\"static/chunks/app-pages-internals.js\"],\"MetadataBoundary\"]\n73:\"$Sreact.suspense\"\n77:I[\"(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/builtin/global-error.js\",[\"app-pages-internals\",\"static/chunks/app-pages-internals.js\"],\"\"]\n91:I[\"(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/lib/metadata/generate/icon-mark.js\",[\"app-pages-internals\",\"static/chunks/app-pages-internals.js\"],\"IconMark\"]\n:HL[\"/_next/static/media/47cbc4e2adbc5db9-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/app/layout.css?v=1763968824704\",\"style\"]\n:HL[\"/_next/static/css/app/(main)/layout.css?v=1763968824704\",\"style\"]\n:HL[\"/_next/static/css/app/(main)/sections/page.css?v=1763968824704\",\"style\"]\n:N1763968824725.5613\n3:\"$EObject.defineProperty(()=\u003e{ctx.componentMod.preloadFont(href,type,ctx.renderOpts.crossOrigin,ctx.nonce)},\\\"name\\\",{value:\\\"\\\"})\"\n4:\"$EObject.defineProperty(()=\u003e{ctx.componentMod.preloadStyle(fullHref,ctx.renderOpts.crossOrigin,ctx.nonce)},\\\"name\\\",{value:\\\"\\\"})\"\n5:\"$EObject.defineProperty(()=\u003e{ctx.componentMod.preloadStyle(fullHref,ctx.renderOpts.crossOrigin,ctx.nonce)},\\\"name\\\",{value:\\\"\\\"})\"\n6:\"$EObject.defineProperty(()=\u003e{ctx.componentMod.preloadStyle(fullHref,ctx.renderOpts.crossOrigin,ctx.nonce)},\\\"name\\\",{value:\\\"\\\"})\"\n2:{\"name\":\"Preloads\",\"key\":null,\"env\":\"Server\",\"stack\":[],\"props\":{\"preloadCallbacks\":[\"$3\",\"$4\",\"$5\",\"$6\"]}}\n7:[]\n9:[]\nb:[[\"Array.map\",\"\",0,0,0,0,false]]\ne:I[\"(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/layout-router.js\",[\"app-p"])self.__next_f.push([1,"ages-internals\",\"static/chunks/app-pages-internals.js\"],\"\"]\n11:I[\"(app-pages-browser)/./node_modules/.pnpm/[email protected][email protected][email protected][email protected]/node_modules/next/dist/client/components/render-from-template-context.js\",[\"app-pages-internals\",\"static/chunks/app-pages-internals.js\"],\"\"]\n12:{}\n13:[[\"Function.all\",\"\",0,0,0,0,true]]\n10:{\"children\":[\"$\",\"$L11\",null,\"$12\",null,\"$13\",1]}\n14:[[\"Function.all\",\"\",0,0,0,0,true]]\nf:{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$a\",null,\"$10\",null,\"$14\",0],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$Y\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\",\"segmentViewBoundaries\":\"$Y\"}\n15:[[\"Function.all\",\"\",0,0,0,0,true]]\nd:{\"name\":\"RootLayout\",\"key\":null,\"env\":\"Server\",\"stack\":[],\"props\":{\"children\":[\"$\",\"$Le\",null,\"$f\",null,\"$15\",1],\"params\":\"$Y\"}}\n16:[[\"RootLayout\",\"webpack-internal:///(rsc)/./src/app/layout.tsx\",26,87,25,1,false]]\n17:[[\"RootLayout\",\"webpack-internal:///(rsc)/./src/app/layout.tsx\",29,94,25,1,false]]\n18:[[\"RootLayout\",\"webpack-internal:///(rsc)/./src/app/layout.tsx\",32,98,25,1,false]]\n1a:[[\"RootLayout\",\"webpack-internal:///(rsc)/./src/app/layout.tsx\",33,102,25,1,false]]\n1c:[[\"Function.all\",\"\",0,0,0,0,true]]\n1e:[[\"Function.all\",\"\",0,0,0,0,true]]\n20:[]\n22:{\"name\":\"NotFound\",\"key\":null,\"env\":\"Server\",\"stack\":[],\"props\":{}}\n23:{\"name\":\"HTTPAccessErrorFallback\",\"key\":null,\"env\":\"Server\",\"owner\":\"$22\",\"stack\":[],\"props\":{\"status\":404,\"message\":\"This page could not be found.\"}}\n24:[]\n25:[]\n26:[]\n27:[]\n28:[]\n29:[]\n2a:[]\n2b:[[\"Function.all\",\"\",0,0,0,0,true]]\n2c:[[\"Function.all\",\"\",0,0,0,0,true]]\n2d:[[\"Function.all\",\"\",0,0,0,0,true]]\n2e:[[\"Function.all\",\"\",0,0,0,0,true]]\n2f:[[\"Array.map\",\"\",0,0,0,0,false],[\"Array.map\",\"\",0,0,0,0,false]]\n34:{}\n35:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n33:{\"children\":[\"$\",\"$L1f\",null,\"$34\",null,\"$35\",1]}\n36:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n32:{\"paral"])self.__next_f.push([1,"lelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$a\",null,\"$33\",null,\"$36\",0],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$Y\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\",\"segmentViewBoundaries\":\"$Y\"}\n37:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n31:{\"name\":\"Layout\",\"key\":null,\"env\":\"Server\",\"stack\":[[\"Function.all\",\"\",0,0,0,0,true]],\"props\":{\"children\":[\"$\",\"$L1d\",null,\"$32\",null,\"$37\",1],\"params\":\"$Y\"}}\n38:{\"name\":\"LayoutWrapper\",\"key\":null,\"env\":\"Server\",\"owner\":\"$31\",\"stack\":[[\"Layout\",\"webpack-internal:///(rsc)/./src/app/(main)/layout.tsx\",12,87,11,16,false]],\"props\":{\"children\":\"$31:props:children\"}}\n39:[[\"LayoutWrapper\",\"webpack-internal:///(rsc)/./src/features/layouts/index.tsx\",37,95,19,98,false]]\n3b:[[\"LayoutWrapper\",\"webpack-internal:///(rsc)/./src/features/layouts/index.tsx\",38,102,19,98,false]]\n3d:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n3e:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n3f:[[\"Function.all\",\"\",0,0,0,0,true]]\n41:{\"name\":\"NotFound\",\"key\":null,\"env\":\"Server\",\"stack\":[[\"Function.all\",\"\",0,0,0,0,true]],\"props\":{}}\n42:{\"name\":\"HTTPAccessErrorFallback\",\"key\":null,\"env\":\"Server\",\"owner\":\"$41\",\"stack\":[],\"props\":{\"status\":404,\"message\":\"This page could not be found.\"}}\n43:[]\n44:[]\n45:[]\n46:[]\n47:[]\n48:[]\n49:[]\n4a:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n4b:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n4c:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n4d:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n4e:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n4f:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n51:{\"name\":\"page\",\"key\":null,\"env\":\"Server\",\"stack\":[[\"Functi"])self.__next_f.push([1,"on.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]],\"props\":{\"params\":\"$@52\",\"searchParams\":\"$@53\"}}\n54:[[\"page\",\"webpack-internal:///(rsc)/./src/app/(main)/sections/page.tsx\",14,87,13,14,false]]\n56:[[\"Array.map\",\"\",0,0,0,0,false],[\"Array.map\",\"\",0,0,0,0,false],[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n57:[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]]\n5b:\"$EObject.defineProperty(async function getViewportReady() {\\n await viewport();\\n return undefined;\\n },\\\"name\\\",{value:\\\"getViewportReady\\\"})\"\n5a:{\"name\":\"__next_outlet_boundary__\",\"key\":null,\"env\":\"Server\",\"stack\":[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]],\"props\":{\"ready\":\"$5b\"}}\n5d:{\"name\":\"StreamingMetadataOutletImpl\",\"key\":null,\"env\":\"Server\",\"stack\":[[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true],[\"Function.all\",\"\",0,0,0,0,true]],\"props\":{}}\n5e:[]\n61:[]\n63:{\"name\":\"NonIndex\",\"key\":null,\"env\":\"Server\",\"stack\":[],\"props\":{\"pagePath\":\"/sections\",\"statusCode\":200,\"isPossibleServerAction\":false}}\n65:{\"name\":\"ViewportTree\",\"key\":null,\"env\":\"Server\",\"stack\":[],\"props\":{}}\n66:[]\n69:{\"name\":\"__next_viewport_boundary__\",\"key\":null,\"env\":\"Server\",\"owner\":\"$65\",\"stack\":[],\"props\":{}}\n6a:[]\n6c:{\"name\":\"MetadataTree\",\"key\":null,\"env\":\"Server\",\"stack\":[],\"props\":{}}\n6d:[]\n70:{\"name\":\"__next_metadata_boundary__\",\"key\":null,\"env\":\"Server\",\"owner\":\"$6c\",\"stack\":[],\"props\":{}}\n71:[]\n72:[]\n75:{\"name\":\"MetadataResolver\",\"key\":null,\"env\":\"Server\",\"owner\":\"$70\",\"stack\":[],\"props\":{}}\n78:[]\n52:{}\n53:\n79:[]\n7a:[]\n7b:[]\n:W[\"warn\",\"$7b\",\"$5d\",\"Server\",\" \\u001b[33m\\u001b[1m⚠\\u001b[22m\\u001b[39m Unsupported metadata themeColor is configured in metadata export in /sections. Please move it to viewport export instead.\\nRead more: https://nextjs.org/docs/app/api-reference/functions/generate-viewport\"]\n7c:[]\n7d:[]\n7e:[[\"Array.map\",\"\",0,0,0,0,false]]\n7f:[[\"Array.map\",\"\",0,0,0,0,"])self.__next_f.push([1,"false]]\n80:[]\n81:[]\n82:[]\n83:[]\n84:[]\n85:[]\n86:[[\"Array.map\",\"\",0,0,0,0,false],[\"Array.map\",\"\",0,0,0,0,false]]\n87:[[\"Array.map\",\"\",0,0,0,0,false],[\"Array.map\",\"\",0,0,0,0,false]]\n88:[[\"Array.map\",\"\",0,0,0,0,false],[\"Array.map\",\"\",0,0,0,0,false]]\n89:[[\"Array.map\",\"\",0,0,0,0,false],[\"Array.map\",\"\",0,0,0,0,false]]\n8a:[]\n8b:[]\n8c:[]\n8d:[]\n8e:[[\"Array.map\",\"\",0,0,0,0,false],[\"Array.map\",\"\",0,0,0,0,false]]\n8f:[[\"Array.map\",\"\",0,0,0,0,false]]\n90:[]\n1:D\"$2\"\n1:null\nc:D\"$d\"\n21:D\"$22\"\n21:D\"$23\"\n"])self.__next_f.push([1,"21:[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"},\"$23\",\"$24\",1],[\"$\",\"div\",null,{\"style\":{\"fontFamily\":\"system-ui,\\\"Segoe UI\\\",Roboto,Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\"\",\"height\":\"100vh\",\"textAlign\":\"center\",\"display\":\"flex\",\"flexDirection\":\"column\",\"alignItems\":\"center\",\"justifyContent\":\"center\"},\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}},\"$23\",\"$27\",1],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":{\"display\":\"inline-block\",\"margin\":\"0 20px 0 0\",\"padding\":\"0 23px 0 0\",\"fontSize\":24,\"fontWeight\":500,\"verticalAlign\":\"top\",\"lineHeight\":\"49px\"},\"children\":404},\"$23\",\"$28\",1],[\"$\",\"div\",null,{\"style\":{\"display\":\"inline-block\"},\"children\":[\"$\",\"h2\",null,{\"style\":{\"fontSize\":14,\"fontWeight\":400,\"lineHeight\":\"49px\",\"margin\":0},\"children\":\"This page could not be found.\"},\"$23\",\"$2a\",1]},\"$23\",\"$29\",1]]},\"$23\",\"$26\",1]},\"$23\",\"$25\",1]]\n"])self.__next_f.push([1,"c:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"w-[100dvw] h-[100dvh]\",\"children\":[\"$\",\"body\",null,{\"id\":\"body\",\"className\":\"__variable_372368 antialiased font-sans bg-white \",\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1b\",null,{\"children\":[\"$\",\"$L1d\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L1f\",null,{},null,\"$1e\",1],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[\"$\",\"$L8\",\"c-not-found\",{\"type\":\"not-found\",\"pagePath\":\"__next_builtin__not-found.js\",\"children\":[\"$21\",[]]},null,\"$20\",0],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\",\"segmentViewBoundaries\":[[\"$\",\"$L8\",null,{\"type\":\"boundary:not-found\",\"pagePath\":\"__next_builtin__not-found.js@boundary\"},null,\"$2b\",1],\"$undefined\",\"$undefined\",[\"$\",\"$L8\",null,{\"type\":\"boundary:global-error\",\"pagePath\":\"__next_builtin__global-error.js\"},null,\"$2c\",1]]},null,\"$1c\",1]},\"$d\",\"$1a\",1]},\"$d\",\"$18\",1]},\"$d\",\"$17\",1]},\"$d\",\"$16\",1]\n"])self.__next_f.push([1,"30:D\"$31\"\n30:D\"$38\"\n40:D\"$41\"\n40:D\"$42\"\n"])self.__next_f.push([1,"40:[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"},\"$42\",\"$43\",1],[\"$\",\"div\",null,{\"style\":\"$21:1:props:style\",\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}},\"$42\",\"$46\",1],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":\"$21:1:props:children:props:children:1:props:style\",\"children\":404},\"$42\",\"$47\",1],[\"$\",\"div\",null,{\"style\":\"$21:1:props:children:props:children:2:props:style\",\"children\":[\"$\",\"h2\",null,{\"style\":\"$21:1:props:children:props:children:2:props:children:props:style\",\"children\":\"This page could not be found.\"},\"$42\",\"$49\",1]},\"$42\",\"$48\",1]]},\"$42\",\"$45\",1]},\"$42\",\"$44\",1]]\n"])self.__next_f.push([1,"30:[\"$\",\"$L3a\",null,{\"children\":[\"$\",\"$L3c\",null,{\"children\":[\"$\",\"$L1d\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L1f\",null,{},null,\"$3e\",1],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[\"$\",\"$L8\",\"c-not-found\",{\"type\":\"not-found\",\"pagePath\":\"__next_builtin__not-found.js\",\"children\":[\"$40\",[]]},null,\"$3f\",0],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\",\"segmentViewBoundaries\":[[\"$\",\"$L8\",null,{\"type\":\"boundary:not-found\",\"pagePath\":\"__next_builtin__not-found.js@boundary\"},null,\"$4a\",1],\"$undefined\",\"$undefined\",\"$undefined\"]},null,\"$3d\",1]},\"$38\",\"$3b\",1]},\"$38\",\"$39\",1]\n"])self.__next_f.push([1,"50:D\"$51\"\n50:[\"$\",\"$L55\",null,{},\"$51\",\"$54\",1]\n59:D\"$5a\"\n5c:D\"$5d\"\n5c:[\"$\",\"$L5f\",null,{\"promise\":\"$@60\"},\"$5d\",\"$5e\",1]\n62:D\"$63\"\n62:null\n64:D\"$65\"\n68:D\"$69\"\n64:[[\"$\",\"$L67\",null,{\"children\":\"$L68\"},\"$65\",\"$66\",1],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"},\"$65\",\"$6a\",1]]\n6b:D\"$6c\"\n6f:D\"$70\"\n74:D\"$75\"\n6f:[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$73\",null,{\"fallback\":null,\"children\":\"$L74\"},\"$70\",\"$72\",1]},\"$70\",\"$71\",1]\n6b:[\"$\",\"$L6e\",null,{\"children\":\"$6f\"},\"$6c\",\"$6d\",1]\n76:[]\n"])self.__next_f.push([1,"0:{\"P\":\"$1\",\"b\":\"development\",\"p\":\"\",\"c\":[\"\",\"sections\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"(main)\",{\"children\":[\"sections\",{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$L8\",\"layout\",{\"type\":\"layout\",\"pagePath\":\"layout.tsx\",\"children\":[\"$\",\"$a\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/app/layout.css?v=1763968824704\",\"precedence\":\"next_static/css/app/layout.css\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"},null,\"$b\",0]],\"$c\"]},null,\"$9\",1]},null,\"$7\",0],{\"children\":[\"(main)\",[\"$\",\"$L8\",\"layout\",{\"type\":\"layout\",\"pagePath\":\"(main)/layout.tsx\",\"children\":[\"$\",\"$a\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/app/(main)/layout.css?v=1763968824704\",\"precedence\":\"next_static/css/app/(main)/layout.css\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"},null,\"$2f\",0]],\"$30\"]},null,\"$2e\",1]},null,\"$2d\",0],{\"children\":[\"sections\",[\"$\",\"$a\",\"c\",{\"children\":[null,[\"$\",\"$L1d\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L1f\",null,{},null,\"$4d\",1],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\",\"segmentViewBoundaries\":[\"$undefined\",\"$undefined\",\"$undefined\",\"$undefined\"]},null,\"$4c\",1]]},null,\"$4b\",0],{\"children\":[\"__PAGE__\",[\"$\",\"$a\",\"c\",{\"children\":[[\"$\",\"$L8\",\"c-page\",{\"type\":\"page\",\"pagePath\":\"(main)/sections/page.tsx\",\"children\":\"$50\"},null,\"$4f\",1],[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/app/(main)/sections/page.css?v=1763968824704\",\"precedence\":\"next_static/css/app/(main)/sections/page.css\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"},null,\"$56\",0]],[\"$\",\"$L58\",null,{\"children\":[\"$L59\",\"$5c\"]},null,\"$57\",1]]},null,\"$4e\",0],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$a\",\"h\",{\"children\":[\"$62\",\"$64\",\"$6b\"]},null,\"$61\",0],false]],\"m\":\"$W76\",\"G\":[\"$77\",[\"$\",\"$L8\",\"ge-svn\",{\"type\":\"global-error\",\"pagePath\":\"__next_builtin__global-error.js\",\"children\":[]},null,\"$78\",0]],\"s\":false,\"S\":false}\n"])self.__next_f.push([1,"68:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"},\"$5a\",\"$79\",0],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"},\"$5a\",\"$7a\",0]]\n59:null\n"])self.__next_f.push([1,"60:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Admin Panel | GastroAGI\"},\"$5d\",\"$7c\",0],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Manage GastroAGI content, users, and configurations through the Admin Panel.\"},\"$5d\",\"$7d\",0],[\"$\",\"link\",\"2\",{\"rel\":\"author\",\"href\":\"https://gastroagi.com\"},\"$5d\",\"$7e\",0],[\"$\",\"meta\",\"3\",{\"name\":\"author\",\"content\":\"GastroAGI Team\"},\"$5d\",\"$7f\",0],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"GastroAGI Admin,Gastroenterology Dashboard,GastroAGI Management,Gastro AGI Backend,Admin Panel GastroAGI,Medical AI Admin,GastroAI Tools Admin\"},\"$5d\",\"$80\",0],[\"$\",\"meta\",\"5\",{\"name\":\"creator\",\"content\":\"GastroAGI Team\"},\"$5d\",\"$81\",0],[\"$\",\"meta\",\"6\",{\"property\":\"og:title\",\"content\":\"Admin Panel | GastroAGI\"},\"$5d\",\"$82\",0],[\"$\",\"meta\",\"7\",{\"property\":\"og:description\",\"content\":\"Manage GastroAGI content, users, and configurations through the Admin Panel.\"},\"$5d\",\"$83\",0],[\"$\",\"meta\",\"8\",{\"property\":\"og:url\",\"content\":\"https://gastroagi.com/admin\"},\"$5d\",\"$84\",0],[\"$\",\"meta\",\"9\",{\"property\":\"og:site_name\",\"content\":\"GastroAGI Admin\"},\"$5d\",\"$85\",0],[\"$\",\"meta\",\"10\",{\"property\":\"og:image:type\",\"content\":\"image/jpeg\"},\"$5d\",\"$86\",0],[\"$\",\"meta\",\"11\",{\"property\":\"og:image:width\",\"content\":\"5472\"},\"$5d\",\"$87\",0],[\"$\",\"meta\",\"12\",{\"property\":\"og:image:height\",\"content\":\"3648\"},\"$5d\",\"$88\",0],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"http://localhost:5454/opengraph-image.jpg?7d84d2c790da1724\"},\"$5d\",\"$89\",0],[\"$\",\"meta\",\"14\",{\"property\":\"og:type\",\"content\":\"website\"},\"$5d\",\"$8a\",0],[\"$\",\"meta\",\"15\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"},\"$5d\",\"$8b\",0],[\"$\",\"meta\",\"16\",{\"name\":\"twitter:title\",\"content\":\"Admin Panel | GastroAGI\"},\"$5d\",\"$8c\",0],[\"$\",\"meta\",\"17\",{\"name\":\"twitter:description\",\"content\":\"Manage GastroAGI content, users, and configurations through the Admin Panel.\"},\"$5d\",\"$8d\",0],[\"$\",\"meta\",\"18\",{\"name\":\"twitter:image\",\"content\":\"https://gastroagi.com/admin-og-image.png\"},\"$5d\",\"$8e\",0],[\"$\",\"link\",\"19\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"1829x2523\"},\"$5d\",\"$8f\",0],[\"$\",\"$L91\",\"20\",{},\"$5d\",\"$90\",0]],\"error\":null,\"digest\":\"$undefined\"}\n"])self.__next_f.push([1,"74:\"$60:metadata\"\n"])